Efficacy and safety for preventing of venous thromboembolic complications in high-risk pregnant women: results of the «BEREG» pregnant women registry ; Эффективность и безопасность профилактики венозных тромбоэмболических осложнений у беременных высокого риска: анализ результатов регистра беременных «БЕРЕГ»

Συγγραφείς: R. I. Stryuk, O. V. Krikunova, E. E. Lokshina, T. A. Gomova, E. E. Fedotova, Р. И. Стрюк, О. В. Крикунова, Э. Э. Локшина, Т. А. Гомова, Е. Е. Федотова

Συνεισφορές: The authors declare no funding. The authors express sincerely gratitude to the staff of the Department of Internal Medicine of the Russian University of Medicine, involved data collection for the «BEREG» registry, Авторы заявляют об отсутствии финансовой поддержки. Авторы выражают благодарность cотрудникам кафедры внутренних болезней ФГБОУ ВО «Российский университет медицины» Минздрава России, которые принимали участие в сборе данных в регистре «БЕРЕГ»

Πηγή: Obstetrics, Gynecology and Reproduction; Vol 19, No 5 (2025); 705-715 ; Акушерство, Гинекология и Репродукция; Vol 19, No 5 (2025); 705-715 ; 2500-3194 ; 2313-7347

Θεματικοί όροι: АСК, VTE, major obstetric syndromes, high risk pregnancies, VTE prophylaxis, antithrombotic therapy, calcium nadroparin, acetylsalicylic acid, ASA, ВТЭО, большие акушерские синдромы, беременные высокого риска, профилактика ВТЭО, антитромботическая терапия, надропарин кальция, ацетилсалициловая кислота

Περιγραφή αρχείου: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2596/1394; Стрюк Р.И., Бернс С.А., Филиппова М.П. и др. Сердечно-сосудистые заболевания и ассоциированные с ними коморбидные состояния как факторы, определяющие неблагоприятные перинатальные исходы при беременности – анализ результатов регистра беременных «БЕРЕГ». Терапевтический архив. 2018;(1):9–16.; Saving Lives, Improving Mothers’ Care: Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2014–16. Eds. K. Knight, K. Bunch, D. Tuffnell et al. National Perinatal Epidemiology Unit: University of Oxford, 2018. 104 p.; Petersen E.E., Davis N.L., Goodman D. et al. Vital signs: pregnancy-related deaths, United States, 2011–2015, and strategies for prevention, 13 States, 2013–2017. Morb Mortal Wkly Rep. 2019;68(18):423. https://doi.org/10.15585/mmwr.mm6818e1.; O'Shaughnessy F., O'Reilly D., Ní Áinle F. Current opinion and emerging trends on the treatment, diagnosis, and prevention of pregnancy-associated venous thromboembolic disease: a review. Transl Res. 2020;225:20–32. https://doi.org/10.1016/j.trsl.2020.06.004.; Здравоохранение в России: статистический сборник. Федеральная служба государственной статистики, 2023. 179 с. Режим доступа: https://youthlib.mirea.ru/ru/resource/6229. [Дата обращения: 21.05.2025].; McColl M.D., Ellison J., Greer I.A. et al. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol. 2000;108(2):272–4. https://doi.org/10.1046/j.1365-2141.2000.01877.x.; Клинические рекомендации – Венозные осложнения во время беременности и послеродовом периоде. Акушерская тромбоэмболия – 2022-2023-2024 (14.02.2022). М.: Министерство здравоохранения Российской Федерации, 2022. 66 с. Режим доступа: http://disuria.ru/_ld/11/1153_kr22O22MZ.pdf. [Дата обращения: 21.05.2025].; Клинические рекомендации – Нормальная беременность – 2023-2024-2025 (15.02.2024). М.: Министерство здравоохранения Российской Федерации, 2024. 58 с. Режим доступа: https://srb-48.gosuslugi.ru/netcat_files/44/136/KR_Normal_naya_beremennost_.pdf. [Дата обращения: 21.05.2025].; Say L., Chou D., Gemmill A., Tunçalp Ö. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33. https://doi.org/10.1016/S2214-109X(14)70227-X10.; Хизроева Д.Х., Бабаева Н.Н., Макацария Н.А. и др. Клиническое значение гемостазиологического скрининга на тромбофилию у беременных с тромбозами в анамнезе. Акушерство, Гинекология и Репродукция. 2022;16(5):528–40. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.361.; Ковалев В.В., Кудрявцева Е.В. Молекулярно-генетические девиации и акушерская патология. Акушерство и гинекология. 2020;(1):26–32.; Zur R.L., Kingdom J.C., Parks W.T., Hobson S.R. The placental basis of fetal growth restriction. Obstet Gynecol Clin North Am. 2020;47(1):81–98. https://doi.org/10.1016/j.ogc.2019.10.008.; Ходжаева З.С., Холин А.М., Чулков В.С., Муминова К.Т. Ацетилсалициловая кислота в профилактике преэклампсии и ассоциированных акушерских и перинатальных осложнений. Акушерство и гинекология. 2018;(8):12–8.; Долгушина В.Ф., Сюндюкова Е.Г., Чулков В.С., Униговская К.А. Риски венозных тромбоэмболических событий при больших акушерских синдромах. Доктор.Ру. 2023;22(1):33–9. https://doi.org/10.31550/1727-2378-2023-22-1-33-39.; Клинические рекомендации – Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде – 2024-2025-2026 (05.09.2024). М.: Министерство здравоохранения Российской Федерации, 2024. 53 с. Режим доступа: http://disuria.ru/_ld/15/1564_kr24O10O16MZ.pdf. [Дата обращения: 21.05.2025].; Hirsh J., Anand S.S., Halperin J.L. et al. Guide to anticoagulant therapy: heparin. A Statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994–3018. https://doi.org/10.1161/01.cir.103.24.2994.; Antman E.M., Handin R. Low-molecular-weight heparins. An intriguing new twist with profound implications. Circulation. 1998;98(4):287–9. https://doi.org/10.1161/01.cir.98.4.287.; Крикунова О.В., Стрюк Р.И. Эноксапарин в алгоритме ведения пациентов с острым коронарным синдромом. Рациональная фармакотерапия в кардиологии. 2018;14(1):131–6. https://doi.org/10.20996/1819-6446-2018-14-1-131-136.; Иртюга О.Б., Шмаков Р.Г., Вавилова Т.В. и др. Дискуссионные вопросы применения антикоагулянтов в профилактике венозных тромбоэмболических осложнений у беременных с сердечно-сосудистыми и системными заболеваниями. Резолюция Совета экспертов. Российский кардиологический журнал. 2023;28(4):5421. https://doi.org/10.15829/1560-4071-2023-5421.; Bistervels I.M., Buchmuller A., Wiegers H.M.G. et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open label, multicentre, randomised, controlled trial. Lancet. 2022;400(10365):1777–87. https://doi.org/10.1016/S0140-6736(22)02128-6.; Cruz-Lemini M., Vazquez J.C., Ullmo J., Llurba E. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022;226(2S):S1126–S1144.e17. https://doi.org/10.1016/j.ajog.2020.11.006.; Hamulyák E.N., Scheres L.J., Marijnen M.C. et al. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020;5(5):CD012852. https://doi.org/10.1002/14651858.CD012852.pub2.; https://www.gynecology.su/jour/article/view/2596

Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/2596
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.652

THROMBOSIS AND BLEEDING COMPLICATIONS AFTER IMPLANTATION OF MECHANICAL CIRCULATORY SUPPORT DEVICES: THE REASONS AND MECHANISMS OF DEVELOPMENT, GENOME-GUIDED CORRECTION. REVIEW: ОСЛОЖНЕНИЯ ТРОМБООБРАЗОВАНИЯ И КРОВОТЕЧЕНИЯ ПОСЛЕ ИМПЛАНТАЦИИ УСТРОЙСТВ МЕХАНИЧЕСКОЙ ПОДДЕРЖКИ КРОВООБРАЩЕНИЯ: ПРИЧИНЫ И МЕХАНИЗМЫ РАЗВИТИЯ, ГЕНОМ – АССОЦИИРОВАННАЯ КОРРЕКЦИЯ. ОБЗОР ЛИТЕРАТУРЫ.

Συγγραφείς: Zhalbinova, M.R., Rakhimova, S.E., Akilzhanov, K.R., Andosova, S.A., Bekbosynova, M.S., Akilzhanova, A.R.

Πηγή: Наука и здравоохранение. :166-174

Θεματικοί όροι: антитромботикалық терапия, gene polymorphism, aspirin, варфарин, гендер полиморфизмі, heart failure, antithrombotic therapy, сердечная недостаточность, 3. Good health, жүрек жеткіліксіздігі, warfarin, аспирин, полиморфизм генов, антитромботическая терапия

Система гемостазу та її регуляція при порушенні функціональної здатності нирок

Συγγραφείς: Melnyk, O.O.

Πηγή: Počki, Vol 6, Iss 3.17, Pp 57-75 (2016)
KIDNEYS; № 3.17 (2016); 57-75
Почки-Počki; № 3.17 (2016); 57-75
Нирки-Počki; № 3.17 (2016); 57-75

Θεματικοί όροι: anticoagulants, antithrombotic therapy in uremic patients, hemostasis system research algorithm, coagulation cascade, Diseases of the genitourinary system. Urology, 3. Good health, platelets, hemostasis, impaired renal function, antiplatelet agents, uremic bleeding and antithrombotic therapy, гемостаз, порушення функції нирок, тромбоцити, коагуляційний каскад, антикоагулянти, антиагреганти, терапія уремічних кровотеч, антитромботична терапія в уремічних пацієнтів, алгоритм дослідження системи гемостазу, нарушение функции почек, тромбоциты, коагуляционный каскад, антикоагулянты, антиагреганты, терапия уремических кровотечений, антитромботическая терапия у уремических пациентов, алгоритм исследования системы гемостаза, RC870-923

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://doaj.org/article/f9e913f075be4ae7a73af190855ede18
https://core.ac.uk/display/87776788
http://kidneys.zaslavsky.com.ua/article/download/76541/116315
http://kidneys.zaslavsky.com.ua/article/view/76541
http://kidneys.zaslavsky.com.ua/article/view/76541

Importance of the Results of VOYAGER PAD Trial for Clinical Practice

Πηγή: Кардиология в Беларуси. :712-720

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, заболевания периферических артерий, peripheral artery diseases, реваскуляризация, revascularization, antithrombotic treatment, 3. Good health, антитромботическая терапия

Фармакогенетика варфарина и клопидогрела по данным реестра пациентов Уральского федерального округа

Συγγραφείς: И. Н. Барышникова, О. М. Шамина, Г. Г. Кетова

Πηγή: Pharmacogenetics and Pharmacogenomics; № 2 (2022); 9-10 ; Фармакогенетика и фармакогеномика; № 2 (2022); 9-10 ; 2686-8849 ; 2588-0527

Θεματικοί όροι: реестр пациентов, полиморфизм генов, антитромботическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/254/244; Исследование фармакогенетики варфарина и клопидогрела для оптимизации антитромботической терапии. Пособие для врачей. Кропачёва Е.С., Комаров А.Л., Донников А.Е., Землянская О.А., Добровольский А.Б., Панченко Е.П. и др. – С. 74. (In Russ).]. http://dna-technology.ru/; Прикладная фармакогенетика: Монография / под ред. Д.А. Сычева – М.: Тверь: ООО «Издательство «Триада»; 2021 – 496 с.; Зотова И.В., Никитин А.Г., Фаттахова Э.Н., Бровкин А.Н., Ходырев Д.С., Лаврикова Е.Ю., Исаева М.Ю., Косухина А.С., Носиков В.В., Затейщиков Д.А. Влияние полиморфизма генов CYP2C9 И VKORC1 на безопасность терапии варфарином. Клиническая практика. 2013;(4):3– 10. http://clinpracticeru.; International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753– 764. DOI:10.1056/NEJMoa0809329.

Διαθεσιμότητα: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/254
https://doi.org/10.37489/2588-0527-2022-2-9-10

Antithrombotic therapy in COVID-19 patients ; Антитромботическая терапия у пациентов с COVID-19

Συγγραφείς: E. V. Slukhanchuk, V. O. Bitsadze, J. Kh. Khizroeva, M. V. Tretyakova, A. S. Shkoda, D. V. Blinov, V. I. Tsibizova, Z. Jinbo, S. Sheena, S. Sсhulman, J.-K. Gris, I. Elalamy, A. D. Makatsariya, Е. В. Слуханчук, В. О. Бицадзе, Д. Х. Хизроева, М. В. Третьякова, А. С. Шкода, Д. В. Блинов, В. И. Цибизова, Ч. Цзиньбо, С. Шина, С. Шульман, Ж.-К. Гри, И. Элалами, А. Д. Макацария

Πηγή: Obstetrics, Gynecology and Reproduction; Vol 16, No 6 (2022); 718-731 ; Акушерство, Гинекология и Репродукция; Vol 16, No 6 (2022); 718-731 ; 2500-3194 ; 2313-7347

Θεματικοί όροι: COVID-19, severe acute respiratory syndrome, SARS-CoV-2, antithrombotic therapy, antiaggregants, anticoagulants, тяжелый острый респираторный синдром, антитромботическая терапия, антиагреганты, антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1521/1072; Schulman S., Sholzberg M., Spyropoulos A.C. et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022;20(10):2214–25. https://doi.org/10.1111/jth.15808.; Spyropoulos A.C., Connors J.M., Douketis J.D. et al. Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022;20(10):2226–36. https://doi.org/10.1111/jth.15809.; Piazza G., Campia U., Hurwitz S. et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2060–72. https://doi.org/10.1016/j.jacc.2020.08.070.; Giannis D., Barish M.A., Goldin M. et al. Incidence of venous thromboembolism and mortality in patients with initial presentation of COVID-19. J Thromb Thrombolysis. 2021;51(4):897–901. https://doi.org/10.1007/s11239-021-02413-7.; Ilowite J., Lisker G., Greenberg H. Digital health technology and telemedicine-based hospital and home programs in pulmonary medicine during the COVID-19 pandemic. Am J Ther. 2021;28(2):e217–e223. https://doi.org/10.1097/MJT.0000000000001342.; Jnr B.A. Use of telemedicine and virtual care for remote treatment in response to COVID-19 pandemic. J Med Syst. 2020;44(7):132. https://doi.org/10.1007/s10916-020-01596-5.; Connors J.M., Brooks M.M., Sciurba F.C. et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021;326(17):1703–12. https://doi.org/10.1001/jama.2021.17272.; Gonzalez-Ochoa A.J., Raffetto J.D., Hernández A.G. et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost. 2021;121(7):944–54. https://doi.org/10.1055/a-1414-5216.; Hozayen S.M., Zychowski D., Benson S. et al. Outpatient and inpatientanticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. EClinicalMedicine. 2021;41:101139. https://doi.org/10.1016/j.eclinm.2021.101139.; Flam B., Wintzell V., Ludvigsson J.F. et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2021;289(3):411–9. https://doi.org/10.1111/joim.13205.; Rivera-Caravaca J.M., Buckley B.J., Harrison S.L. et al. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021;205:1–7. https://doi.org/10.1016/j.thromres.2021.06.014.; Kleindorfer D.O., Towfighi A., Chaturvedi S. et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–e467. https://doi.org/STR.0000000000000375.; Rentsch C.T., Beckman J.A., Tomlinson L. et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021;372:n311. https://doi.org/10.1136/bmj.n311.; Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775.; Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.; Tritschler T., Mathieu M.-E., Skeith L. et al. Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020;18(11):2958–67. https://doi.org/10.1111/jth.15094.; ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Patrick R Lawler P.R., Goligher E.C., Berger J.S. et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802. https://doi.org/10.1056/NEJMoa2105911.; Spyropoulos A.C., Goldin M., Giannis D. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612–20. https://doi.org/10.1001/jamainternmed.2021.6203.; Sholzberg M., Tang G.H., Rahhal H. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400. https://doi.org/10.1136/bmj.n2400.; Battistoni I., Francioni M., Morici N. et al. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. J Cardiovasc Med (Hagerstown). 2022;23(4):264–71. https://doi.org/10.2459/JCM.0000000000001284.; Cohen S.L., Gianos E., Barish M.A. et al. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost. 2021;121(8):1043–53. https://doi.org/10.1055/a-1366-9656.; Di Castelnuovo A., Costanzo S., Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost. 2021;121(8):1054–65. https://doi.org/10.1055/a-1347-6070.; Ionescu F., Jaiyesimi I., Petrescu I. et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. Eur J Haematol. 2021;106(2):165–74. https://doi.org/10.1111/ejh.13533.; Sholzberg M., da Costa B.R., Tang G.H. et al. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis. Res Pract Thromb Haemost. 2021;5(8):e12638. https://doi.org/10.1002/rth2.12638.; Gonzalez-Porras J.R., Belhassen-Garcia M., Lopez-Bernus A. et al. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study. Sao Paulo Med J. 2021;140(1):123–33. https://doi.org/10.1590/1516-3180.2021.0098.R1.08062021.; Meizlish M.L., Goshua G., Liu Y. et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity scorematched analysis. Am J Hematol. 2021;96(4):471–9. https://doi.org/10.1002/ajh.26102.; Morici N., Podda G., Birocchi S. et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. Eur J Clin Invest. 2022;52(5):e13735. https://doi.org/10.1111/eci.13735.; Smadja D.M., Bonnet G., Gendron N. et al. Intermediate- vs. standarddose prophylactic anticoagulation in patients with COVID-19 admitted in medical ward: A propensity score-matched cohort study. Front Med (Lausanne). 2021;8:747527. https://doi.org/10.3389/fmed.2021.747527.; Lopes R.D., de Barros E. Silva P.G.M., Furtado R.H.M. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253–63. https://doi.org/10.1016/S0140-6736(21)01203-4.; RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143–51. https://doi.org/10.1016/S0140-6736(21)01825-0.; Berger J.S., Kornblith L.Z., Gong M.N.et al. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(3):227–36. https://doi.org/10.1001/jama.2021.23605.; Shen L., Qiu L., Liu D. et al. The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19. Cardiovasc Drugs Ther. 2022;36(1):113–20. https://doi.org/10.1007/s10557-020-07133-3.; Poli D., Antonucci E., Ageno W. et al. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register. Intern Emerg Med. 2022;17(4):1013–21. https://doi.org/10.1007/s11739-021-02891-w.; Zinellu A., Paliogiannis P., Carru C., Mangoni A.A. INR and COVID-19 severity and mortality: A systematic review with meta-analysis and metaregression. Adv Med Sci. 2021;66(2):372–80. https://doi.org/10.1016/j.advms.2021.07.009.; Fumagalli S., Trevisan C., Del Signore S. et al. COVID-19 and atrial fibrillation in older patients: does oral anticoagulant therapy provide a survival benefit? – An insight from the GeroCovid registry. Thromb Haemost. 2022;122(1):105–12. https://doi.org/10.1055/a-1503-3875.; Protasiewicz M., Reszka K., Kosowski W. et al. Anticoagulation prior to COVID-19 infection has no impact on 6 months mortality: A propensity score-matched cohort study. J Clin Med. 2022;11(2):352. https://doi.org/10.3390/jcm11020352.; Gozzo L., Viale P., Longo L. et al. The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review. Front Pharmacol. 2020;11:1307. https://doi.org/10.3389/fphar.2020.01307.; RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143–51. https://doi.org/10.1016/S2213-2600(21)00435-5.; Steffel J., Verhamme P., Potpara T.S.et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93. https://doi.org/10.1093/eurheartj/ehy136.; Foerster K.I., Hermann S., Mikus G., Haefeli W.E. Drug–drug interactions with direct oral anticoagulants. Clin Pharmacokinet. 2020;59(8):967–80. https://doi.org/10.1007/s40262-020-00879-x.; Cuker A., Tseng E.K., Nieuwlaat R. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv. 2022;6(2):664–71. https://doi.org/10.1182/bloodadvances.2021005945.; Robinson S., Longmuir K., Pavord S. Haematology of pregnancy. Medicine. 2017;45(4):251–5. https://doi.org/10.1016.j.mpmed.2017.01.002.; D’Souza R., Malhamé I., Teshler L. et al. A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19. Acta Obstet Gynecol Scand. 2020;99(9):1110–20. https://doi.org/10.1111/aogs.13962.; Servante J., Swallow G., Thornton J.G. et al. Haemostatic and thromboembolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth. 2021;21(1):1–14. https://doi.org/10.1186/s12884-021-03568-0.; Daru J., White K., Hunt B.J. COVID-19, thrombosis and pregnancy.Thromb Update. 2021;5:100077. https://doi.org/10.1016/j.tru.2021.100077.; Lee Y.R., Blanco D.D. Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically ill patients. J Thromb Thrombolysis. 2017;44(3):386–91. https://doi.org/10.1007/s11239-017-1535-8.; Hendren N.S., De Lemos J.A., Ayers C. et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2021;143(2):135–44. https://doi.org/10.1161/CIRCULATIONAHA.120.051936.; Sawadogo W., Tsegaye M., Gizaw A., Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ NutR Prev Health. 2022;5(1):10–8. https://doi.org/10.1136/bmjnph-2021-000375.; Hunt B.J. Hemostasis at extremes of body weight. Semin Thromb Hemost. 2018;44(7):632–9. https://doi.org/10.1055/s-0038-1661385.; Belančić A., Kresović A., Rački V. Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. Obes Med. 2020;19:100259. https://doi.org/10.1016/j.obmed.2020.100259.; Wang T.-F., Milligan P.E., Wong C.A. et al. Efficacy and safety of highdose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111(1):88–93. https://doi.org/10.1160/TH13-01-0042.; He Z., Morrissey H., Ball P. Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients – Actual Weight-based vs Fixed. Crit Rev Oncol Hematol. 2017;113:191–4. https://doi.org/10.1016/j.critrevonc.2017.03.022.; Liu Y., Du X., Chen J. et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6–e12. https://doi.org/10.1016/j.jinf.2020.04.002.; Miranda S., Le Cam-Duchez V., Benichou J. et al. Adjusted value of thromboprophylaxis in hospitalized obese patients: a comparative study of two regimens of enoxaparin: the ITOHENOX study. Thromb Res. 2017;155:1–5. https://doi.org/10.1016/j.thromres.2017.04.011.; INSPIRATION Investigators; Sadeghipour P., Talasaz A., Rashidi F. et al. Eeffect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620–30. https://doi.org/10.1001/jama.2021.4152.; Moores L.K., Tritschler T., Brosnahan S. et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest. 2022;162(1):213–25. https://doi.org/10.1016/j.chest.2022.02.006.; Cohoon K.P., Mahé G., Tafur A.J., Spyropoulos A.C. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Pract Thromb Haemost. 2020;4(4):510–7. https://doi.org/10.1002/rth2.12358.; Stevens S.M., Woller S.C., Kreuziger L.B. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608. https://doi.org/10.1016/j.chest.2021.07.055.; Wang Y., Zhu F., Wang C. et al. Children hospitalized with severe COVID-19 in Wuhan. Pediatr Infect Dis J. 2020;39(7):e91–e94. https://doi.org/10.1097/INF.0000000000002739.; Cruz A.T., Zeichner S.L. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics. 2020;145(6):e20200834. https://doi.org/10.1542/peds.2020-0834.; Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med. 2020;383(4):334–46. https://doi.org/10.1056/NEJMoa2021680.; Goldenberg N.A., Sochet A., Albisetti M. et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020;18(11):3099–105. https://doi.org/10.1111/jth.15073.; Sochet A.A., Morrison J.M., Jaffray J. et al. Enoxaparin thromboprophylaxis in children hospitalized for COVID-19: A phase 2 trial. Pediatrics. 2022;150(1):e2022056726. https://doi.org/10.1542/peds.2022-056726.; Shafiee M.A., Hosseini S.F., Mortazavi M. et al. Anticoagulation therapy in COVID-19 patients with chronic kidney disease. J Res Med Sci. 2021;26:63. https://doi.org/10.4103/jrms.JRMS_875_20.; Fernandez P., Saad E.J., Barrionuevo A.D. et al. The incidence, risk factors and impact of acute kidney injury in hospitalized patients due to COVID-19. Medicina (B Aires). 2021;81(6):922–30.; Stevens J.S., Velez J.C.Q., Mohan S. Continuous renal replacement therapy and the COVID pandemic. Semin Dial. 2021;34(6):561–6. https://doi.org/10.1111/sdi.12962.; Arnold F., Westermann L., Rieg S. et al. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC Nephrol. 2020;21(1):486. https://doi.org/10.1186/s12882-020-02150-8.; Billett H., Reyes-Gil M., Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin and apixaban on mortality. Thromb Haemost. 2020;120(12):1691–9. https://doi.org/10.1055/s-0040-1720978.; Attallah N., Gupta S., Madhyastha R. et al. Anticoagulation in COVID-19 patients requiring continuous renal replacement therapy. Anaesth Crit Care Pain Med. 2021;40(3):100841. https://doi.org/10.1016/j.accpm.2021.100841.; Schünemann H.J., Cushman M., Burnett A.E. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198–225. https://doi.org/10.1182/bloodadvances.2018022954.; PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Cook D., Meade M., Guyatt G. et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305–14. https://doi.org/10.1056/NEJMoa1014475.; Perepu U.S., Chambers I., Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multicenter, open-label, randomized controlled trial. J Thromb Haemost. 2021;19(9):2225–34. https://doi.org/10.1111/jth.1545.; REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher E.C., Bradbury C.A., McVerry B.J. et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89. https://doi.org/10.1056/NEJMoa2103417.; REMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury C.A., Lawler P.R., Stanworth S.J. et al. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1247–59. https://doi.org/10.1001/jama.2022.2910.; Bikdeli B., Talasaz A.H., Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost. 2022;122(1):131–41. https://doi.org/10.1055/a-1485-2372.; Oliynyk O., Barg W., Slifirczyk A. et al. Comparison of the effect of unfractionated heparin and enoxaparin sodium at different doses on the course of COVID-19-associated coagulopathy. Life (Basel). 2021;11()10:1032. https://doi.org/10.3390/life11101032.; El-Ghiaty M.A, Shoieb S.M., El-Kadi A.O. Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms. Med Hypotheses. 2020;144:110033. https://doi.org/10.1016/j.mehy.2020.110033.; Vincent J.-L., Levi M., Hunt B.J. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med. 2021;10(2):214–20. https://doi.org/10.1016/S2213-2600(21)00455-0.; Roberts L.N., Whyte M.B., Georgiou L. et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347–50. https://doi.org/10.1182/blood.2020008086.; Rashidi F., Barco S., Kamangar F. et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res. 2021;198:135–8. https://doi.org/10.1016/j.thromres.2020.12.001.; Patell R., Bogue T., Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342–6. https://doi.org/10.1182/blood.2020007938.; Giannis D., Allen S.L., Tsang J. et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838–47. https://doi.org/10.1182/blood.2020010529.; Lui D.T.W., Li Y.K., Lee C.H. et al. A prospective study of the impact of glycaemic status on clinical outcomes and anti-SARS-CoV-2 antibody responses among patients with predominantly non-severe COVID-19. Diabetes Res Clin Pract. 2022;185:109232. https://doi.org/10.1016/j.diabres.2022.109232.; Chioh F.W., Fong S.-W., Young B.E. et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife. 2021;10:e64909. https://doi.org/10.7554/eLife.6490.; Spyropoulos A.C., Cohen S.L., Gianos E. et al. Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Res Pract Thromb Haemost. 2021;5(2):296–300. https://doi.org/10.1002/rth2.12486.; Goldin M., Lin S.K., Kohn N. et al. External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. J Thromb Thrombolysis. 2021;52(4):1032–5. https://doi.org/10.1007/s11239-021-02504-5.; Ramacciotti E., Agati L.B., Calderaro D. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50–9. https://doi.org/10.1016/S0140-6736(21)02392-8.; https://www.gynecology.su/jour/article/view/1521

Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/1521
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.370

Patient with non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Part 2. Secondary prophylaxis ; Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 2. Вторичная профилактика

Συγγραφείς: A. A. Kulesh, S. N. Yanishevsky, D. A. Demin, L. I. Syromyatnikova, O. I. Vinogradov, А. А. Кулеш, С. Н. Янишевский, Д. А. Демин, Л. И. Сыромятникова, О. И. Виноградов

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 3 (2023); 4-10 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 3 (2023); 4-10 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-3

Θεματικοί όροι: комбинированная антитромботическая терапия, atherothrombotic stroke, transient ischemic attack, secondary prevention, combined antithrombotic therapy, атеротромботический инсульт, транзиторная ишемическая атака, вторичная профилактика

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2022/1528; Кулеш АА, Янишевский СН, Демин ДА и др. Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 1. Диагностика. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):10-8. doi:10.14412/2074-27112023-2-10-18; Wang Y, Wang Y, Zhao X, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi:10.1056/NEJMoa1215340; Johnston SC, Easton JD, Farrant M, et al. Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-25. doi:10.1056/NEJMoa1800410; Johnston SC, Amarenco P, Denison H, et al. THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-17. doi:10.1056/NEJMoa1916870; Krishnan K, Law ZK, Minhas JS, et al. Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. Clin Med (Lond). 2022 Sep;22(5):449-54. doi:10.7861/clinmed.20210597; Pan Y, Elm JJ, Li H, et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019 Dec 1;76(12):1466-73. doi:10.1001/jamaneurol.2019.2531; Amarenco P, Denison H, Evans SR, et al. THALES Steering Committee and Investigators*. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke. 2020 Dec;51(12):3504-13. doi:10.1161/STROKEAHA.120.032239; Wang Y, Pan Y, Li H, et al. Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology. 2022 Jul 5;99(1):e46-e54. doi:10.1212/WNL.0000000000200355; Dawson J, Merwick A, Webb A, et al. European Stroke Organisation. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J. 2021 Jun;6(2):VI. doi:10.1177/23969873211027006; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375; Amin HP, Madsen TE, Bravata DM, et al. American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease. Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting: A Scientific Statement from the American Heart Association. Stroke. 2023 Mar;54(3):e109-e121. doi:10.1161/STR.0000000000000418. Epub 2023 Jan 19.; Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-30. doi:10.1056/NEJMoa1709118; Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019 Feb 26;139(9):1134-45. doi:10.1161/CIRCULATIONAHA.118.035864; Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021 Oct 14;42(39):4013-24. doi:10.1093/eurheartj/ehab390; Dawson J, Bejot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022 Sep;7(3):I-II. doi:10.1177/23969873221100032; Арутюнов ГП, Амелин АВ, Вознюк ИА и др. Значение результатов исследования COMPASS в изменении подходов к лечению пациентов неврологического профиля. Заключение совета экспертов от 18 декабря 2021 г. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(4):1-6. doi:10.17116/jnevro202212204194; Psychogios M, Brehm A, Lopez-Cancio E, et al. European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease. Eur Stroke J. 2022 Sep;7(3):III-IV. doi:10.1177/23969873221099715; Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014 Jan 25;383(9914):333-41. doi:10.1016/S01406736(13)62038-3; Ntaios G, Pearce LA, Meseguer E, et al. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke. 2019 Nov;50(11):3184-90. doi:10.1161/STROKEAHA.119.025813; Hawkes MA, Braksick SA, Zhang W, et al. Can we stop the stuttering in stroke? Interventions in 40 patients with acute lacunes. J Neurol Sci. 2019 Jun 15;401:1-4. doi:10.1016/j.jns.2019.04.009; Berberich A, Schneider C, Reiff T, et al. Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes. Stroke. 2019 Apr;50(4):1007-9. doi:10.1161/STROKEAHA.118.023789; Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009 May;8(5):453-63. doi:10.1016/S14744422(09)70058-4; Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-37. doi:10.1093/eurheartj/ehab484; Zeitouni M, Sabouret P, Kerneis M, et al. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):324-33. doi:10.1093/ehjcvp/pvaa077; Вознюк ИА, Шамалов НА, Ежов МВ и др. Оптимизация гиполипидемической терапии у пациентов, перенесших ишемический инсульт. Резолюция Совета экспертов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(6):152-61. doi:10.17116/jnevro2020120061152; Кухарчук ВВ, Ежов МВ, Сергиенко ИВ и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002; Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021 May;325:99-109. doi:10.1016/j.atherosclerosis.2021.03.039; Giugliano RP, Pedersen TR, Saver JL, et al. FOURIER Investigators. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 May;51(5):1546-54. doi:10.1161/STROKEAHA.119.027759; Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020 Nov1;134:69-73. doi:10.1016/j.amjcard.2020.08.018; Hsu C, Saver JL, Ovbiagele B, et al. Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and Meta-Regression. JAMA Neurol. 2023 May 1;80(5):506-15. doi:10.1001/jamaneurol.2023.0218; Dolui S, Detre JA, Gaussoin SA, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Neurol. 2022 Apr 1;79(4):380-9. doi:10.1001/jamaneurol.2022.0074; SPRINT MIND Investigators for the SPRINT Research Group; Nasrallah IM, Pajewski NM, Auchus AP, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019 Aug 13;322(6):524-34. doi:10.1001/jama.2019.10551; Nasrallah IM, Gaussoin SA, Pomponio R, et al. SPRINT Research Group. Association of Intensive vs Standard Blood Pressure Control with Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. JAMA Neurol. 2021 May 1;78(5):568-77. doi:10.1001/jamaneurol.2021.0178; Paciaroni M, Agnelli G, Caso V, et al. Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. Cerebrovasc Dis. 2009;28(2):119-23. doi:10.1159/000223436. Epub 2009 Jun 5.; Staszewski J, Brodacki B, Kotowicz J, Stepien A. Intravenous insulin therapy in the maintenance of strict glycemic control in nondiabetic acute stroke patients with mild hyperglycemia. J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):150-4. doi:10.1016/j.jstrokecerebrovasdis.2009.11.013. Epub 2010 Jul 10.; Rosso C, Corvol JC, Pires C, et al. Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke. 2012 Sep;43(9):2343-9. doi:10.1161/STROKEAHA.112.657122. Epub 2012 Jun 14.; Johnston KC, Bruno A, Pauls Q, et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019 Jul 23;322(4):326-35. doi:10.1001/jama.2019.9346; Shou J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis. 2015;24:1961-8. doi:10.1016/j.jstrokecerebrovasdis.2015.04.004; Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi:10.1093/eurheartj/ehz486; American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi:10.2337/dc22S009; Joseph JJ, Deedwania P, Acharya T, et al. American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022 Mar;145(9):e722e759. doi:10.1161/CIR.0000000000001040; Naylor R, Rantner B, Ancetti S, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2022 May 20:S1078-5884(22)00237-4. doi:10.1016/j.ejvs.2022.04.011; Bonati LH, Kakkos S, Berkefeld J, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. Eur Stroke J. 2021 Jun;6(2):IXLVII. doi:10.1177/23969873211012121; Eriksson H, Koskinen S, Nuotio K, et al. Predictive Factors for Pre-operative Recurrence of Cerebrovascular Symptoms in Symptomatic Carotid Stenosis. Eur J Vasc Endovasc Surg. 2020 Dec;60(6):809-15. doi:10.1016/j.ejvs.2020.08.044; Cui CL, Dakour-Aridi H, Lu JJ, et al. In-Hospital Outcomes of Urgent, Early, or Late Revascularization for Symptomatic Carotid Artery Stenosis. Stroke. 2022 Jan;53(1):100-7. doi:10.1161/STROKEAHA.120.032410; Чернявский МА, Иртюга ОБ, Янишевский СН и др. Российский консенсус по диагностике и лечению пациентов со стенозом сонных артерий. Российский кардиологический журнал. 2022;27(11):5284. doi:10.15829/1560-4071-2022-5284; Gao P, Wang T, Wang D, et al. CASSISS Trial Investigators. Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial. JAMA. 2022 Aug 9;328(6):534-42. doi:10.1001/jama.2022.12000; Turan TN, Zaidat OO, Gronseth GS, et al. Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee. Neurology. 2022 Mar 22;98(12):486-98. doi:10.1212/WNL.0000000000200030

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2022
https://doi.org/10.14412/2074-2711-2023-3-4-10

Coagulation Disorders in Infective Endocarditis: Role of Pathogens, Biomarkers, Antithrombotic Therapy (Systematic Review) ; Роль нарушений в системе гемостаза при инфекционном эндокардите: связь с возбудителем, биомаркеры, место антитромботической терапии (систематический обзор)

Συγγραφείς: A. S. Pisaryuk, V. A. Zamarashkina, N. B. Safarova, N. M. Povalyaev, E. O. Kotova, U. I. Babukhina, E. M. Koltsova, Zh. D. Kobalava, А. С. Писарюк, В. А. Замарашкина, Н. Б. Сафарова, Н. М. Поваляев, Е. О. Котова, Ю. И. Бабухина, Е. М. Кольцова, Ж. Д. Кобалава

Συνεισφορές: This paper has been supported by the RUDN University Strategic Academic Leadership Program, Публикация выполнена при поддержке Программы стратегического академического лидерства РУДН

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 3 (2022); 320-331 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 3 (2022); 320-331 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: антитромботическая терапия, immunothrombosis, hemostasis, embolic events, biomarkers of coagulation and fibrinolysis, prevention of embolism, antithrombotic therapy, иммунотромбоз, гемостаз, эмболические события, биомаркеры системы гемостаза, профилактика эмболий

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2755/2321; https://www.rpcardio.com/jour/article/view/2755/2328; Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222-3232. DOI:10.1093/eurheartj/ehz620.; Marques A, Cruz I, Caldeira D, et al. Risk factors for in-hospital mortality in infective endocarditis. Arq Bras Cardiol. 2020;114(1):1-8. DOI:10.36660/abc.20180194.; Моисеев В.С., Кобалава Ж.Д., Писарюк А.С. и др. Инфекционный эндокардит: клиническая характеристика и исходы (7-летний опыт лечения и наблюдения в многопрофильной городской больнице). Кардиология. 2018;58(12):62-5. DOI:10.18087/cardio.2018.12.10192.; Российский статистический ежегодник. М.: Росстат; 2021 [цитировано 09.01.2022]. Доступно из: https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2021.pdf].; Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации (2021). [цитировано 09.01.2022. Доступно из: https://scardio.ru/content/Guidelines/2020/KP_Inf_Endokardit-unlocked.pdf.; Lichtman S. Treatment of subacute bacterial endocarditis: current results. Ann Intern Med. 1943;19(5):787. DOI:10.7326/0003-4819-19-5-787.; Писарюк А.С., Котова Е.О., Караулова Ю.Л., Мильто А.С. История учения об инфекционном эндокардите. Клиническая Фармакология и Терапия. 2018;(2):77-84.; Durante-Mangoni E, Molaro R, Iossa D. The Role of Hemostasis in Infective Endocarditis. Curr Infect Dis Rep. 2014;16(11):1-9. DOI:10.1007/s11908-014-0435-8.; Bancsi M, Veltrop M, Bertina RM, Thompson J. Role of phagocytosis in activation of the coagulation system in Streptococcus sanguis endocarditis. Infect Immun. 1996;64(12):5166-70. DOI:10.1128/iai.64.12.5166-5170.1996.; Durante-Mangoni E, Iossa D, Molaro R, et al. Prevalence and significance of two major inherited thrombophilias in infective endocarditis. Intern Emerg Med. 2015;10(5):587-94. DOI:10.1007/s11739-015-1214-8.; Gafter-Gvili A, Mansur N, Bivas A, et al. Thrombocytopenia in Staphylococcus aureus bacteremia: Risk factors and prognostic importance. Mayo Clin Proc. 2011;86(5):389-96. DOI:10.4065/mcp.2010.0705.; Icli A, Tayyar S, Varol E, et al. Mean platelet volume is increased in infective endocarditis and decreases after treatment. Med Princ Pract. 2013;22(3):270-3. DOI:10.1159/000345393.; Колесникова Н.В., Самойленко Е.С. Роль цитокинов в патогенезе инфекционного эндокардита. Иммунология. 2020;41(3):2628. DOI:10.33029/0206-4952-2020-41-3-262-268.; Liesenborghs L, Meyers S, Vanassche T, Verhamme P. Coagulation: At the heart of infective endocarditis. J Thromb Haemost. 2020;18(5):995-1008. DOI:10.1111/jth.14736.; Мальцева Н.В., Лапутенко Т.А., Смирнова А.Ш., Кан С.Л. Полиморфизм и синергизм генов системы гемостаза в патогенезе инфекционного эндокардита. Молекулярная Медицина. 2019;17(4):45-51. DOI:10.29296/24999490-2019-04-07.; Sy RW, Chawantanpipat C, Richmond DR, Kritharides L. Thrombocytopenia and Mortality in Infective Endocarditis. J Am Coll Cardiol. 2008;51(18):1824-25. DOI:10.1016/j.jacc.2008.01.034.; Чапаева Н. Н., Бахарева Ю. С., Серяпина Ю. В., и др. Роль полиморфизма генов системы гемостаза в диагностике тромбоэмболических осложнений при небактериальном тромботическом эндокардите. Journal of Siberian Medical Sciences. 2013;(4):59. DOI:10.1017/CBO9781107415324.004.; Chambers ST, Murdoch DR, Morris A, et al. HACEK Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort. PLoS One. 2013;8(5):e63181. DOI:10.1371/journal.pone.0063181.; Nomura R, Otsugu M, Naka S, et al. Contribution of the interaction of Streptococcus mutans serotype k strains with fibrinogen to the pathogenicity of infective endocarditis. Infect Immun. 2014;82(12): 5223-34. DOI:10.1128/IAI.02164-14.; Jung CJ, Yeh CY, Hsu R Bin, et al. Endocarditis pathogen promotes vegetation formation by inducing intravascular neutrophil extracellular traps through activated platelets. Circulation. 2015; 131(6):571-81. DOI:10.1161/CIRCULATIONAHA.114.011432.; Gragnano F, Crisci M, Bigazzi MC, et al. Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. Angiology. 2018;69(2):103-12. DOI:10.1177/0003319717708070.; Liesenborghs L, Verhamme P, Vanassche T. Staphylococcus aureus, master manipulator of the human hemostatic system. J Thromb Haemost. 2018;16(3):441-54. DOI:10.1111/jth.13928.; Sullam PM, Bayer AS, Foss WM, Cheung AL. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun. 1996;64(12):4915-21. DOI:10.1128/iai.64.12.4915-4921.1996.; Fitzgerald JR, Loughman A, Keane F, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcγRIIa receptor. Mol Microbiol. 2006;59(1):212-30. DOI:10.1111/j.13652958.2005.04922.x.; Kupferwasser LI, Yeaman MR, Shapiro SM, et al. In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental staphylococcus aureus endocarditis microbiological, histopathologic, and echocardiographic anal. Circulation. 2002;105(6):746-52. DOI:10.1161/hc0602.103721.; Forsblom E, Lepäntalo A, Wartiovaara-Kautto U, et al. Changes in hemostasis parameters in nonfatal methicillin-sensitive Staphylococcus aureus bacteremia complicated by endocarditis or thromboembolic events: a prospective gender-age adjusted cohort study. APMIS. 2019;127(7):515-28. DOI:10.1111/apm.12955.; Demirbag R. Using the D-dimer test in infective endocarditis. Turk Kardiyol Dern Arsivi-Archives Turkish Soc Cardiol. 2013;41(7):595-7. DOI:10.5543/tkda.2013.09483.; Buyukasýk NS, Ileri M, Alper A, et al. Increased Blood Coagulation and Platelet Activation in Patients with Infective Endocarditis and Embolic Events. Clin Cardiol. 2004;27(3):154-8. DOI:10.1002/clc.4960270312.; Snipsøyr MG, Ludvigsen M, Petersen E, et al. A systematic review of biomarkers in the diagnosis of infective endocarditis. Int J Cardiol. 2016;202:564-70. DOI:10.1016/j.ijcard.2015.09.028.; Виноградова Т.Л., Чипигина Н.С., Озерецкий К.С., и др. Тромбоэмболические осложнения при подостром инфекционном эндокардите. Вестник РГМУ. 2005;8(47):48-54.; Виноградова Т., Чипигина Н., Озерецкий К., Петухов Е. Тромбоэмболический синдром и системный гемостаз при подостром инфекционном эндокардите. Врач. 2005;(5):22-4.; Habib G. Management of infective endocarditis. Heart. 2006;92(1):124-30. DOI:10.1136/hrt. 2005.063719.; Таранова М.В., Андросова Т.В., Козловская Л.В., и др. Прогностическое значение тромбоэмболических осложнений при инфекционном эндокардите, возможности профилактики. Клиническая Медицина. 2018;96(2):129-36.; Hubert S, Thuny F, Resseguier N, et al. Prediction of symptomatic embolism in infective endocarditis: Construction and validation of a risk calculator in a multicenter cohort. J Am Coll Cardiol. 2013;62(15):1384-92. DOI:10.1016/j.jacc.2013.07.029.; Rizzi M, Ravasio V, Carobbio A, et al. Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). BMC Infect Dis. 2014;14(1):230. DOI:10.1186/1471-2334-14-230.; Hook EW, Sande MA. Role of the vegetation in experimental Streptococcus viridans endocarditis. Infect Immun. 1974;10(6):1433-8. DOI:10.1128/iai.10.6.1433-1438.1974.; Levison ME, Carrizosa J, Tanphaichitra D, et al. Effect of aspirin on thrombogenesis and on production of experimental aortic valvular Streptococcus viridans endocarditis in rabbits. Blood. 1977;49(4):645-50. DOI:10.1182/blood.v49.4.645.645.; Thorig L, Thompson J, Eulderink F. Effect of warfarin on the induction and course of experimental Staphylococcus epidermis endocarditis. Infect Immun. 1977;17(3):504-9. DOI:10.1128/iai.17.3.504-509.1977.; Johnson CE, Dewar HA. Effect of sulphinpyrazone on the development of experimental endocardial vegetations. Cardiovasc Res. 1982;16(11):657-62. DOI:10.1093/cvr/16.11.657.; Pujadas R, Escrivá E, Fernández F, et al. [Effect of various doses of aspirin on the development of aseptic thrombotic aortic endocarditis experimentally induced in the rabbit]. Rev Esp Cardiol. 1988;41(1):31-4 (In Spanish).; Nicolau DP, Freeman CD, Nightingale CH, et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun. 1993;61(4):1593-5. DOI:10.1128/iai.61.4. 1593-1595.1993.; Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1995;39(8):1748-51. DOI:10.1128/AAC.39.8.1748.; Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 1998;9(4):2279. DOI:10.1016/S0924-8579(97)00056-3.; Nicolau DP, Tessier A PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 1999;11(2):159-61. DOI:10.1016/S0924-8579(98)00092-2.; Kupferwasser LI, Yeaman MR, Shapiro SM et al. Acetylsalicylic Acid Reduces Vegetation Bacterial Density, Hematogenous Bacterial Dissemination, and Frequency of Embolic Events in Experimental Staphylococcus aureus Endocarditis Through Antiplatelet and Antibacterial Effects. Circulation. 1999;99(21):2791-7. DOI:10.1161/01.CIR.99.21.2791.; Veloso TR, Que YA, Chaouch A, et al. Prophylaxis of experimental endocarditis with antiplatelet and antithrombin agents: A role for long-term prevention of infective endocarditis in humans? J Infect Dis. 2015;211(1):72-9. DOI:10.1093/infdis/jiu426.; Hannachi N, Ogé-Ganaye E, Baudoin JP, et al. Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria. Front Pharmacol. 2020;11:863. DOI:10.3389/fphar.2020.00863.; Katz LN, Elek SR. Combined heparin and chemotherapy in subacute bacterial endocarditis. J Am Med Assoc. 1944;124(3):149-52. DOI:10.1001/jama.1944.02850030017004.; Loewe L, Rosenblatt P, Greene HJ. Combined penicillin and heparin therapy of subacute bacterial endocarditis. JAMA. 1944;124(3):144-9. DOI:10.1001/jama.1944.02850030012003.; Priest WS, Smith JM, McGee CJ. The Effect of Anticoagulants on the Penicillin Therapy and the Pathologic Lesion of Subacute Bacterial Endocarditis. N Engl J Med. 1946;235(20):699-706. DOI:10.1056/NEJM194611142352001.; Thill CJ, Meyer OO. Experiences with penicillin and dicumarol in the treatment of subacute bacterial endocarditis. Am J Med Sci. 1947;213(3):300-7. DOI:10.1097/00000441-194703000-00005.; Wilson WR, Geraci JE, Danielson GK, et al. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation. 1978;57(5):1004-7. DOI:10.1161/01.CIR.57.5.1004.; Paschalisa C, Pugsley W, John R, Harrison MJG. Rate of cerebral embolic events in relation to antibiotic and anticoagulant therapy in patients with bacterial endocarditis. Eur Neurol. 1990;30(2):87-9. DOI:10.1159/000117317.; Taha TH, Durrant SS, Mazeika PK, et al. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med. 1992;231(5):543-6. DOI:10.1111/j.1365-2796.1992.tb00971.x.; Демин А.А., Дробышева В.П., Мильто А.С и др. Инфекционный эндокардит: дезагреганты в лечении нарушений гемостаза. Клиническая Фармакология и Терапия. 1995;(1):51-2.; Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol. 2003;42(5):775-80. DOI:10.1016/S07351097(03)00829-5.; Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis. 2007;44(9):1180-6. DOI:10.1086/513197.; Chan KL, Tam J, Dumesnil JG, et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis. 2008;46(1):85-92. DOI:10.1086/524021.; Pepin J, Tremblay V, Bechard D, et al. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect. 2009;15(2):193-9. DOI:10.1111/j.1469-0691.2008.02665.x.; Eisen DP, Corey GR, McBryde ES, et al. Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J Infect. 2009;58(5):3328. DOI:10.1016/j.jinf.2009.03.006.; Snygg-Martin U, Rasmussen R V, Hassager C, et al. Warfarin therapy and incidence of cerebrovascular complications in left-sided native valve endocarditis. Eur J Clin Microbiol Infect Dis. 2011;30(2):1517. DOI:10.1007/s10096-010-1063-3.; Habib A, Irfan M, Baddour LM, et al. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Europace. 2013;15(2):227-35. DOI:10.1093/europace/eus292.; Ong E, Mechtouff L, Bernard E, et al. Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature. J Neurol. 2013;260(5):1339-42. DOI:10.1007/s00415012-6802-1.; Eisen DP, Mcbryde ES. An association between aspirin use in human cases of infective endocarditis and reduced systemic embolism is shown in meta-analysis of observational studies. J Infect Dis Adv Access. 2015;212(4):673-4. DOI:10.1093/infdis/jiv131.; Pathickal SM, Park TE, Sharma R. Clinical Outcomes Associated With the Use of Anticoagulant and Antiplatelet Agents in Patients Undergoing Treatment for Infective Endocarditis: A Pilot Study. Clin Ther. 2020;42(9):1828-38. DOI:10.1016/j.clinthera.2020.07.007.; Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-128. DOI:10.1093/eurheartj/ehv319.; Preston AH, Williams S, Archer J. A review of the role of anticoagulation for patients with infective endocarditis and embolic stroke. Clin Case Reports. 2016;4(5):513-6. DOI:10.1002/ccr3.556.; Sloane KL, Raymond SB, Rabinov JD, Singhal AB. Mechanical Thrombectomy in Stroke from Infective Endocarditis: Case Report and Review. J Stroke Cerebrovasc Dis. 2020;29(1):104501. DOI:10.1016/j.jstrokecerebrovasdis.2019.104501.; Lacey MJ, Raza S, Rehman H, et al. Coronary Embolism: A Systematic Review. Cardiovasc Revascularization Med. 2020;21(3):367-74. DOI:10.1016/j.carrev.2019.05.012.; Leeten K, Jacques N, Lancellotti P, Oury C. Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand? Front Cell Dev Biol. 2021;9:716302. DOI:10.3389/fcell.2021.716302.; Vanassche T, Peetermans WE, Herregods MC, et al. Anti-thrombotic therapy in infective endocarditis. Expert Rev Cardiovasc Ther. 2011;9(9):1203-19. DOI:10.1586/erc.11.100.; https://www.rpcardio.com/jour/article/view/2755

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2755
https://doi.org/10.20996/1819-6446-2022-06-14

Antithrombotic Therapy and the Nearest Forecast of Pulmonary Embolism in Rutine Clinical Practice (Data of the Regional Vascular Center of the Ryazan Region) ; Антитромботическая терапия и ближайший прогноз тромбоэмболии легочной артерии в рутинной клинической практике (данные регионального сосудистого центра Рязанской области)

Συγγραφείς: N. N. Nikulina, Yu. V. Terekhovskaya, S. S. Yakushin, Н. Н. Никулина, Ю. В. Тереховская, С. С. Якушин

Συνεισφορές: The study was performed with the support of the Ryazan State Medical University., Исследование проведено при поддержке Рязанского государственного медицинского университета им. академика И.П. Павлова.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 2 (2022); 135-142 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 2 (2022); 135-142 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: прогноз, PE, antithrombotic therapy, prognosis, антитромботическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2707/2294; Barco S, Mahmoudpour SH, Valerio L, et al. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med. 2020;8(3):277-87. DOI:10.1016/S2213-2600(19)30354-6.; Никулина Н.Н., Тереховская Ю.В. Эпидемиология тромбоэмболии легочной артерии в современном мире: анализ заболеваемости, смертности и проблем их изучения. Российский Кардиологический Журнал. 2019;(6):103-8]. DOI:10.15829/1560-4071-2019-6-103-108.; Laporte S, Mismetti P, Décousus H, et al.; RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation. 2008;117(13):1711-6. DOI:10.1161/CIRCULATIONAHA.107.726232.; Shah P, Arora S, Kumar V, et al. Short-term outcomes of pulmonary embolism: A National Perspective. Clin Cardiol. 2018;41(9):1214-24. DOI:10.1002/clc.23048.; Meyer G, Vicaut E, Danays T, et al for the PEITHO Investigators. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med. 2014;370(15):1402-11. DOI:10.1056/ NEJMoa1302097.; Мензоров М.В., Филимонова В.В., Эрлих А.Д., и др. Почечная дисфункция у пациентов с тромбоэмболией лёгочной артерии по данным регистра СИРЕ-НА. Российский кардиологический журнал. 2021;26(2S):4422. DOI:10.15829/1560-4071-2021-4422.; Черепанова Н.А., Муллова И.С., Павлова Т.В., и др. Тромболитическая терапия в лечении пациентов с тромбоэмболией легочной артерии невысокого риска по данным регистра СИРЕНА. Рациональная Фармакотерапия в Кардиологии. 2021;17(3):4017. DOI:10.20996/1819-6446-2021-06-11.; Konstantinides S, Torbicki A, Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35(43):3033-69. DOI:10.1093/eurheartj/ehu283.; Konstantinides SV, Meyer G, Becattini C, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory So-ciety (ERS). Eur Heart J. 2020;41(4):543-603. DOI:10.1093/eurheartj/ehz405.; Черепанова Н.А., Муллова И.С., Киселев А.Р., и др. Тромболитическая терапия у нормотензивных пациентов с тромбоэмболией легочной артерии (по данным ретроспективного исследования). Рациональная Фармакотерапия в Кардиологии 2020;16(5):742-8. DOI:10.20996/1819-6446-2020-10-13.; Куракина Е.А., Дупляков Д.В., Хохлунов С.М., и др. Синкопе при немассивной тромбоэмболии легочной артерии как предиктор высокого риска летального исхода. Рациональная Фармакотерапия в Кардиологии. 2012;8(2):158-62. DOI:10.20996/1819-6446-2012-82-158-162.; Муллова И.С., Павлова Т.В., Хохлунов С.М., Дупляков Д.С. Прогностическое значение ЭКГ у пациентов с тромбоэмболией легочной артерии. Рациональная Фармакотерапия в Кардиологии. 2019;15(1):63-8. DOI:10.20996/1819-6446-2019-15-1-63-68.; Мазур Е.С., Мазур В.В., Рабинович Р.М., Бачурина М.А. Клинико-ангиопульмонографические соотношения при тромбоэмболии легочной артерии. Терапевтический Архив. 2021;93(4): 363–8. DOI:10.26442/00403660.2021.04.200674.; Тереховская Ю.В., Окороков В.Г., Никулина Н.Н. Современная позиция антикоагулянтов при острой ТЭЛА: достижения, ограничения, перспективы. Российский Медико-биологический Вестник им. Академика И.П. Павлова. 2019;27(1):93106. DOI:10.23888/PAVLOVJ201927193-106.; https://www.rpcardio.com/jour/article/view/2707

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2707
https://doi.org/10.20996/1819-6446-2022-04-13

Features of pathogenesis and risk factors of in-hospital ischemic stroke ; Особенности патогенеза и факторы риска внутригоспитального ишемического инсульта

Συγγραφείς: S. V. Kolomentsev, N. V. Tsygan, I. A. Voznyuk, S. N. Yanishevskiy, E. I. Shermatyuk, O. M. Ilyina, I. V. Litvinenko, С. В. Коломенцев, Н. В. Цыган, И. А. Вознюк, С. Н. Янишевский, Е. И. Шерматюк, О. М. Ильина, И. В. Литвиненко

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 6 (2022); 25-32 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 6 (2022); 25-32 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-6

Θεματικοί όροι: антитромботическая терапия, perioperative stroke, stroke of another established etiology, comorbidity, antithrombotic therapy, периоперационный инсульт, инсульт другой установленной этиологии, коморбидность

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1917/1473; Mashour GA, Moore LE, Lele AV, et al. Perioperative care of patients at high risk for stroke during or after non-cardiac, non-neurologic surgery: consensus statement from the Society for Neuroscience in Anesthesiology and Critical Care. J Neurosurg Anesthesiol. 2014 Oct;26(4):273-85. doi:10.1097/ANA.0000000000000087; Цыган НВ, Андреев РВ, Пелешок АС и др. Периоперационный мозговой инсульт в хирургии клапанов сердца: патогенез, клиника, диагностика, лечение и профилактика. Журнал неврологии и психиатрии им. C.C. Корсакова. 2018;118(4):52-60. doi:10.17116/jnevro20181184152-60; Emmett ES, Douiri A, Marshall IJ, et al. A comparison of trends in stroke care and outcomes between in-hospital and community-onset stroke – The South London Stroke Register. PLoS One. 2019 Feb 21;14(2):e0212396. doi:10.1371/journal.pone.0212396; Коломенцев СВ, Цыган НВ, Вознюк ИА и др. Факторы риска периоперационного ишемического инсульта у пациентов общехирургического профиля. Вестник Российской Военно-медицинской академии. 2019;3(67):75-7. doi:10.32863/1682-7392-2019-3-67-75-77; Bang OY, Seok JM, Kim SG, et al. Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol. 2011 Jun;7(2):53-9. doi:10.3988/jcn.2011.7.2.53. Epub 2011 Jun 28.; Коломенцев СВ, Одинак ММ, Вознюк ИА и др. Ишемический инсульт у стационарного пациента. Современный взгляд на состояние проблемы. Вестник Российской Военно-медицинской академии. 2017;2(58):206-12.; Mrkobrada M, Chan MTV, Cowan D, Campbell D; NeuroVISION Investigators. Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. Lancet. 2019 Sep 21;394(10203):1022-9. doi:10.1016/S0140-6736(19)31795-7. Epub 2019 Aug 15.; Alberts MJ, Brass LM, Perry A, et al. Evaluation times for patients with in-hospital strokes. Stroke. 1993 Dec;24(12):1817-22. doi:10.1161/01.str.24.12.1817. Erratum in: Stroke. 1994 Mar;25(3):717.; Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001 Dec 1;32(12):2735-40. doi:10.1161/hs1201.100209; Tsiskaridze A, Lindgren A, Qureshi AI. Treatment-Related stroke. Cambridge: University Printing House; 2016.; Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi:10.1016/0021-9681(87)90171-8; Клинические рекомендации по проведению тромболитической терапии у пациентов с ишемическим инсультом [архив]. Доступно по ссылке: http://stopinsult.ru/uploads/default/files/%D0%9F%D1%80%D0%BE%D1%82%D0%BE%D0%BA%D0%BE%D0%BB%20%D0%A2%D0%9B%D0%A2%202015.pdf (дата обращения 12.06.2020).; Реперфузионная терапия ишемического инсульта. Клинический протокол. Москва; 2019.; Приказ МЗ РФ № 928н от 15 ноября 2012 г. «Об утверждении порядка оказания медицинской помощи больным с острыми нарушениями мозгового кровообращения». Доступно по ссылке: https://rulaws.ru/acts/Prikaz-MinzdravaRossii-ot-15.11.2012-N-928n/ (дата обращения 12.06.2020).; Приказ МЗ РФ № 1740 от 29 декабря 2012 г. «Об утверждении стандарта специализированной медицинской помощи при инфаркте мозга». Доступно по ссылке: https://www.rosminzdrav.ru/documents/8970-prikaz-ministerstva-zdravoohraneniyarossiyskoy-federatsii-ot-29-dekabrya-2012-g1740n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-infarkte-mozga (дата обращения 12.06.2020).; Azzimondi G, Nonino F, Fiorani L, et al. Incidence of stroke among inpatients in a large Italian hospital. Stroke. 1994 Sep;25(9):1752-4. doi:10.1161/01.str.25.9.1752; Российские клинические рекомендации по диагностике и лечению ишемического инсульта и ТИА у взрослых. Ассоциации неврологов России. Всероссийское общество неврологов. 2020. 208 с. Доступно по ссылке: https://npcpn.ru/vracham/klinicheskie-rekomendatsii (дата обращения 03.12.2020).; Костенко ЕВ, Полунин ВС, Полунина ИВ. Влияние сопутствующей заболеваемости на особенности реабилитационного процесса после инсульта. Лечебное дело. 2017;(4):27-33.; Филатов АГ, Тарашвили ЭГ. Этиология и социальная значимость фибрилляции предсердий. Анналы аритмологии. 2012;9(2):5-13.; Дедов ИИ, Шестакова МВ, Викулова ОК и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144-59. doi:10.14341/DM9686; Воробьев АИ, Васильев СА, Городецкий ВМ и др. Гиперкоагуляционный синдром: классификация, патогенез, диагностика, терапия. Гематология и трансфузиология. 2016;61(3):116-22. doi:10.18821/0234-5730-2016-61-3-116-122; Овечкин АМ, Романова ТЛ. Послеоперационное обезболивание: оптимизация подходов с точки зрения доказательной медицины. Русский медицинский журнал. 2006;14(12):865-72.; Цыган НВ, Андреев РВ, Пелешок АС и др. Послеоперационная мозговая дисфункция при хирургических операциях на клапанах сердца в условиях искусственного кровообращения. Вестник Российской Военно-медицинской академии. 2015;2(50):198-203.; Perera KS, Vanassche T, Bosch J, et al; ESUS Global Registry Investigators. Global Survey of the Frequency of Atrial FibrillationAssociated Stroke: Embolic Stroke of Undetermined Source Global Registry. Stroke. 2016 Sep;47(9):2197-202. doi:10.1161/STROKEAHA.116.013378. Epub 2016 Aug 9.; Ornello R, Degan D, Tiseo C, et al. Distribution and Temporal Trends From 1993 to 2015 of Ischemic Stroke Subtypes: A Systematic Review and Meta-Analysis. Stroke. 2018 Apr;49(4):814-9. doi:10.1161/STROKEAHA.117.020031. Epub 2018 Mar 13.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1917
https://doi.org/10.14412/2074-2711-2022-6-25-32

Long-term outcomes of coronary artery bypass graft surgery in patients with widespread atherosclerotic lesions of the coronary and peripheral vascular basins (based on the REGATA long-term antithrombotic therapy registry) ; Отдаленные исходы коронарного шунтирования у больных с распространенным атеросклеротическим поражением коронарного и периферического сосудистых бассейнов (по данным регистра длительной антитромботической терапии РЕГАТА)

Συγγραφείς: E. N. Krivosheeva, A. L. Komarov, D. M. Galyautdinov, E. E. Vlasova, R. S. Akchurin, E. P. Panchenko, Е. Н. Кривошеева, А. Л. Комаров, Д. М. Галяутдинов, Э. Е. Власова, Р. С. Акчурин, Е. П. Панченко

Πηγή: Aterotromboz = Atherothrombosis; № 2 (2021); 30-43 ; Атеротромбоз; № 2 (2021); 30-43 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2021-2

Θεματικοί όροι: эндартерэктомия, antithrombotic therapy, rivaroxaban, risk of thrombotic complications, multivessel coronary artery disease, coronary artery bypass graft surgery, endarterectomy, антитромботическая терапия, ривароксабан, риск тромботических осложнений, многососудистая ИБС, коронарное шунтирование

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/254/276; Aboyans V., Ricco J., Bartelink M., Björck M., Brodmann M., Cohnert T. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;39(9):763–816. https://doi.org/10.1093/eurheartj/ehx095.; Bhatt D. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA. 2006;295(2):180. https://doi.org/10.1001/jama.295.2.180.; Steg P., Bhatt D., Wilson P., D’Agostino R., Ohman E., Röther J. et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA. 2007;297(11):1197. https://doi.org/10.1001/jama.297.11.1197.; Alberts M., Bhatt D., Mas J., Ohman E., Hirsch A., Rother J. et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30(19):2318–2326. https://doi.org/10.1093/eurheartj/ehp355.; Комаров А.Л., Новикова Е.С., Гуськова Е.В., Яровая Е.Б., Самко А.Н., Панченко Е.П. Новые возможности антитромботической терапии больных с периферическим и распространенным атеросклеротическим поражением. Рациональная фармакотерапия в кардиологии. 2018;14(2):272–283. https://doi.org/10.20996/1819-6446-2018-14-2-272-283.; Fowkes F. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27(15):1861–1867. https://doi.org/10.1093/eurheartj/ehl114.; Naylor A., Mehta Z., Rothwell P., Bell P. Carotid Artery Disease and Stroke During Coronary Artery Bypass:a Critical Review of the Literature. Eur J Vasc Endovasc Surg. 2002;23(4):283–294. https://doi.org/10.1053/ejvs.2002.1609.; Aichner F., Topakian R., Alberts M., Bhatt D., Haring H., Hill M. et al. High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH registry. Eur J Neurol. 2009;16(8):902–908. https://doi.org/10.1111/j.1468-1331.2009.02614.x.; Bhatt D., Eagle K., Ohman E., Hirsch A., Goto S., Mahoney E. et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA. 2010;304(12):1350. https://doi.org/10.1001/jama.2010.1322.; Resnick H., Lindsay R., McDermott M., Devereux R., Jones K., Fabsitz R., Howard B. Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality. Circulation. 2004;109(6):733–739. https://doi.org/10.1161/01.cir.0000112642.63927.54.; Kleinegris M.C., ten Cate H., ten Cate-Hoek A.J. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. Thromb Haemost. 2013;110(08):233–243. https://doi.org/10.1160/th13-01-0032.; Комаров А.Л., Новикова Е.С., Добровольский А.Б., Яровая Е.Б., Гуськова Е.В., Самко А.Н., Панченко Е.П. Прогностическое значение оценки по шкале DAPT и уровня D-димера у больных, подвергаемых плановым чрескожным коронарным вмешательствам. Кардиологический вестник. 2018;(2):39–47. https://doi.org/10.17116/Cardiobulletin201813239.; Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet. 2000;355(9201):346–351. https://doi.org/10.1016/s0140-6736(99)07199-8.; Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. N Engl J Med. 2007;357(3):217–227. https://doi.org/10.1056/nejmoa065959.; van Rein N., Heide-Jørgensen U., Lijfering W., Dekkers O., Sørensen H., Cannegieter S. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation. 2019;139(6):775–786. https://doi.org/10.1161/circulationaha.118.036248.; Eikelboom J., Connolly S., Bosch J., Dagenais G., Hart R., Shestakovska O. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2007;377(14):1319–1330. https://doi.org/10.1056/nejmoa1709118.; Bosch J., Eikelboom J., Connolly S., Bruns N., Lanius V., Yuan F. et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outco mes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027–1035. https://doi.org/10.1016/j.cjca.2017.06.001.; Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;41(3):407–477. https://doi.org/10.1093/eurheartj/ehz425.; Барбараш О.Л., Карпов Ю.А., Кашталап В.В., Бощенко А.А., Руда М.М., Акчурин Р.С. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. https://doi.org/10.15829/29/1560-4071-2020-4076.; Connolly S., Eikelboom J., Bosch J., Dagenais G., Dyal L., Lanas F. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205–218. https://doi.org/10.1016/s0140-6736(17)32458-3.; Anand S., Bosch J., Eikelboom J., Connolly S., Diaz R., Widimsky P. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. https://doi.org/10.1016/s0140-6736(17)32409-1.; Lamy A., Eikelboom J., Sheth T., Connolly S., Bosch J., Fox K. et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. J Am Coll Cardiol. 2019;73(2):121–130. https://doi.org/10.1016/j.jacc.2018.10.048.; Sharma M., Hart R., Connolly S., Bosch J., Shestakovska O., Ng K. et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139(9):1134–1145. https://doi.org/10.1161/circulationaha.118.035864.; https://www.aterotromboz.ru/jour/article/view/254

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/254
https://doi.org/10.21518/2307-1109-2021-11-2-30-43

Хроническая ишемическая болезнь сердца. Кто нуждается в усилении антитромботической терапии?

Συγγραφείς: Панина, Ю. Н., Вишневский, В. И., Громнацкий, Н. И.

Θεματικοί όροι: медицина, внутренние болезни, кардиология, хроническая ишемическая болезнь сердца, лечение, антитромботическая терапия, коморбидные состояния, ишемический риск

Relation: http://dspace.bsu.edu.ru/handle/123456789/49267

Διαθεσιμότητα: http://dspace.bsu.edu.ru/handle/123456789/49267

Влияние фибрилляции предсердий на отдаленные результаты у пациентов с бифуркационными поражениями коронарного русла, подвергавшихся стентированию

Συγγραφείς: Д. Хелимский, О. Крестьянинов, А. Бадоян, А. Баранов, Р. Утегенов, И. Бессонов, С. Сапожников

Πηγή: Патология кровообращения и кардиохирургия, Vol 25, Iss 4 (2021)

Θεματικοί όροι: антитромботическая терапия, бифуркационное поражение коронарного русла, фибрилляция предсердий, чрескожное коронарное вмешательство, Surgery, RD1-811

Περιγραφή αρχείου: electronic resource

Relation: https://journalmeshalkin.ru/index.php/heartjournal/article/view/1052; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

Σύνδεσμος πρόσβασης: https://doaj.org/article/6a6b67ac6526472ab23aaa9c3db72f58

Особенности вторичной профилактики у пациентов с мультифокальным артериальным поражением. Часть 2: возможности лечения ; Diagnosis and Secondary Prevention in Patients with Multifocal Arterial Disease. Part 2: Treatment Options

Συγγραφείς: Grachev, V. G., Vedenskaya, S. S., Smolenskaya, O. G., Грачев, В. Г., Веденская, С. С., Смоленская, О. Г.

Θεματικοί όροι: CARDIOVASCULAR DISEASE, POLYVASCULAR DISEASE, SCREENING, RISK ASSESSMENT, SECONDARY PREVENTION, ANTITHROMBOTIC THERAPY, СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ, МУЛЬТИФОКАЛЬНОЕ АРТЕРИАЛЬНОЕ ПОРАЖЕНИЕ, СКРИНИНГ, СТРАТИФИКАЦИЯ РИСКА, ВТОРИЧНАЯ ПРОФИЛАКТИКА, АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ

Περιγραφή αρχείου: application/pdf

Relation: Scopus; http://elib.usma.ru/handle/usma/7316

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7316

COVID-19 and Cardiovascular System. Part 3. COVID-19 Current Treatment Approaches: Evidence-Based Review ; COVID-19 и сердечно-сосудистая система. Часть III. Подходы к лечению COVID-19: обзор современной доказательной базы

Συγγραφείς: M. K. Vasilchenko, A. A. Ivannikov, A. N. Yesaulenko, Kh. G. Alidzhanova, S. S. Petrikov, М. К. Васильченко, А. А. Иванников, А. Н. Эсауленко, Х. Г. Алиджанова, С. С. Петриков

Πηγή: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 10, № 3 (2021); 438-451 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 10, № 3 (2021); 438-451 ; 2541-8017 ; 2223-9022

Θεματικοί όροι: немедикаментозное лечение COVID-19, clinical trials, therapeutic options for COVID-19, anti-SARS-CoV-2 antibody products, antiviral therapy, immunomodulators, antithrombotic therapy, non-pharmacological interventions, клинические исследования, подходы к терапии COVID-19, терапия на основе антител, противовирусная терапия, иммуномодулирующая терапия, антитромботическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1204/967; https://www.jnmp.ru/jour/article/view/1204/1059; Global Coronavirus COVID-19 Clinical Trial Tracker. URL: https://www.covid-trials.org/ [Дата обращения 5 июня 2021 г.]; Randomised evaluation of COVID-19 therapy (RECOVERY). URL: https://www.recoverytrial.net/files/protocol-archive/recovery-protocol-v6-0-2020-05-14.pdf [Дата обращения 7 июля 2021 г.]; Randomised Evaluation of COVID-19 Therapy (RECOVERY). URL: https://www.clinicaltrials.gov/ct2/show/NCT04381936 [Дата обращения 13 мая 2021 г.]; RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605–612. PMID: 33545096 https://doi.org/10.1016/S0140-6736(21)00149-5; RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19. URL: https://www.recoverytrial.net/news/recovery-trial-closes-recruitment-to-colchicine-treatmentfor-patients-hospitalised-with-covid-19 [Дата обращения 7 июня 2021 г.]; RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomized controlled, open-label, platform trial. Lancet. 2021;397(10289):2049–2059. PMID: 34000257 https://doi.org/10.1016/S0140-6736(21)00897-7; Mrukowicz J, Rot M. Дексаметазон при тяжелом течении COVID-19. URL: https://empendium.com/ru/chapter/B33.1394.54 [Дата обращения 13 мая 2021 г.]; RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020;383(21):2030–2040. PMID: 33031652 https://doi.org/10.1056/NEJMoa2022926; Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020. No clinical benefit from use of hydroxychloroquinein hospitalized patients with COVID-19. URL: https://www.recoverytrial.net/files/hcqrecovery-statement-050620-final-002.pdf [Дата обращения 10 июня 2021 г.]; Mrukowicz J, Gajowiec K. Исследование RECOVERY: лопинавир/ритонавир неэффективен у пациентов с COVID-19 URL: https://empendium.com/ru/chapter/B33.1394.65 [Дата обращения: 10 июня 2021 г.]; RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352. PMID: 33031764 https://doi.org/10.1016/S0140-6736(20)32013-4; “Solidarity” clinical trial for COVID-19 treatments. URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/globalresearch-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-forcovid-19-treatments [Дата обращения 26 мая 2021 г.]; Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. PMID: 32732190 https://doi.org/10.1136/bmj.m2980; Corticosteroids for COVID-19. Living Guidance. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 [Дата обращения 12 июня 2021 г.]; Therapeutics and COVID-19: living guideline, 20 November 2020. URL: https://apps.who.int/iris/handle/10665/336729 [Дата обращения 16 июня 2021 г.]; Therapeutics and COVID-19: living guideline. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1 [Дата обращения 20 июня 2021 г.]; Lloyd EC, Gandhi TN, Petty LA. Monoclonal antibodies for COVID-19. JAMA. 2021;325(10):1015. PMID: 33544136 https://doi.org/10.1001/jama.2021.1225; BMJ Best Practice. Coronavirus disease 2019 (COVID-19). URL: https://bestpractice.bmj.com/topics/en-gb/3000201/emergingtxs#referencePop947 [Дата обращения 12 июня 2021 г.]; Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizesmonoclonal-antibodies-treatment-covid-19-0 [Дата обращения 23 июня 2021 г.]; Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonalantibody-bamlanivimab [Дата обращения 21 июня 2021 г.]; Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. PMID: 33475701 https://doi.org/10.1001/jama.2021.0202; Anti-SARS-CoV-2 Monoclonal Antibodies. URL: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/anti-sarscov-2-monoclonal-antibodies/ [Дата обращения 13 июня 2021 г.]; Phase 3 trial shows regen-cov™ (casirivimab with imdevimab) antibody cocktail reduced hospitalization or death by 70% in non-hospitalized covid-19 patients. URL: https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-shows-regen-covtm-casirivimabimdevimab-antibody [Дата обращения 13 июня 2021 г.]; Fact sheet for health care providers emergency use authorization (EUA) of casirivimab and imdevimab. URL: https://www.fda.gov/media/143892/download [Дата обращения 7 июня 2021 г.]; Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, un cóctel de anticuerpos neutralizantes, en pacientes ambulatorios con Covid-19. N Engl J Med. 2021;384(3):238–251. PMID: 33332778 https://doi.org/10.1056/NEJMoa2035002; EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab). URL: https://www.ema.europa.eu/en/news/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimabimdevimab [Дата обращения 14 июня 2021 г.]; Anti-SARS-CoV-2 Antibody Products. URL: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/ [Дата обращения 15 июня 2021 г.]; ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384(10):905–914. PMID: 33356051 https://doi.org/10.1056/NEJMoa2033130; EMA issues advice on use of regdanvimab for treating COVID-19. URL: https://www.ema.europa.eu/en/news/ema-issues-advice-useregdanvimab-treating-covid-19 [Дата обращения 7 июля 2021 г.]; Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Plat. URL: https://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=446 [Дата обращения 15 июля 2021 г.]; Celltrion’s COVID-19 treatment candidate receives Korean MFDS Conditional Marketing Authorisation. URL: https://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=442 [Дата обращения 15 июня 2021 г.]; Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol. 2020;190(3):e154–e156. PMID: 32593180 https://doi.org/10.1111/bjh.16981; RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19-preliminary report. N Engl J Med. 2021;384(8):693–704. PMID: 32678530 https://doi.org/10.1056/NEJMoa2021436; Libster R, Marc GP, Wappner D, Coviello S, Bianchi A, Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. https://doi.org/10.1101/2020.11.20.20234013 URL: https://www.medrxiv.org/content/10.1101/2020.11.20.20234013v1 [Дата обращения 7 июля 2021 г.]; NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms. URL: https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescentplasma-emergency-department-patients-mild-symptoms [Дата обращения 16 июня 2021 г.]; Буланов А.Ю., Костин А.И., Петриков С.С., Лысенко М.А., Попугаев К.А., Фомина Д.С. и др. Клиническое использование реконвалесцентной плазмы в терапии новой коронавирусной инфекции: московский опыт. Анестезиология и реаниматология. 2020;(6-2):33–39. https://doi.org/10.17116/anaesthesiology202006233; Immunoglobulins: SARS-CoV-2 Specific. URL: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/ivig---sars-cov-2/ [Дата обращения 17 июня 2021 г.]; Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81(2):318–356. PMID: 32283154 https://doi.org/10.1016/j.jinf.2020.03.044; Hou X, Tian L, Zhou L, Jia X, Kong L, Xue Y, et al. Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study. Virol J. 2021;18(1):101. PMID: 34020680 https://doi.org/10.1186/s12985-021-01575-3; Zhang J, Yang Y, Yang N, Ma Y, Zhou Q, Li W, et al. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review. Ann Transl Med. 2020;8(10):625. PMID: 32566562 https://doi.org/10.21037/atm-20-3305; Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. PMID: 32020029 https://doi.org/10.1038/s41422-020-0282-0; Table 2a. Remdesivir: Selected Clinical Data. URL: https://www.covid19treatmentguidelines.nih.gov/tables/table-2a/ [Дата обращения 10 июня 2021 г.]; Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826. PMID: 32445440 https://doi.org/10.1056/NEJMoa2007764; Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009;103(6):539–547. PMID: 19695159 https://doi.org/10.1179/000349809X12459740922138; Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30(9):445–455. PMID: 25130507 https://doi.org/10.1016/j.pt.2014.07.005; Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760. PMID: 32135219 https://doi.org/10.1016/j.antiviral.2020.104760; Arévalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, et al. Ivermectin reduces coronavirus infection in vivo: a mouse experimental model. Sci Rep. 2021;11(1):7132. PMID: 33785846 https://doi.org/10.1101/2020.11.02.363242; Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDAapproved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. PMID: 32251768 https://doi.org/10.1016/j.antiviral.2020.104787; Chaccour C, Abizanda G, Irigoyen-Barrio Á, Casellas A, Aldaz A, Martínez-Galán F, et al. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Sci Rep. 2020;10(1):17073. PMID: 33051517 https://doi.org/10.1038/s41598-020-74084-y; Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther. 2020;108(4):762–765. PMID: 32378737 https://doi.org/10.1002/cpt.1889; Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 y sepsis viral: observaciones e hipótesis. Lancet. 2020;395(10235):1517-1520. PMID: 32311318 https://doi.org/10.1016/S0140-6736(20)30920-X; van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D. Colchicine for acute gout. Cochrane Database Syst Rev. 2014;(8): CD006190. PMID: 25123076 https://doi.org/10.1002/14651858.CD006190.pub2; Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: the GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e2013136. PMID: 32579195 https://doi.org/ 10.1001/jamanetworkopen.2020.13136; Rabbani AB, Parikh RV, Rafique AM. Colchicine for the Treatment of Myocardial Injury in Patients with Coronavirus Disease 2019 (COVID-19)—an Old Drug with New Life? JAMA Netw Open. 2020;3(6):e2013556. PMID: 32579190 https://doi.org/10.1001/jamanetworkopen.2020.1355; Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;9(8):924–932. PMID: 34051877 https://doi.org/10.1016/S2213-2600(21)00222-8.; Vincent JL. COVID-19: it’s all about sepsis. Future Microbiol. 2021;16:131–133. PMID: 33491491 https://doi.org/10.2217/fmb-2020-0312; Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11(478):eaau5266. PMID: 30728287 https://doi.org/10.1126/scitranslmed.aau5266; Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci. 2016;19(9):977–984. PMID: 27803785; Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(22):2292–2300. PMID: 33180097 https://doi.org/10.1001/jama.2020.22760; Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 2009;83(7):3039–3048. PMID: 19004938 https://doi.org/10.1128/JVI.01792-08; Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. PMID: 32171076 https://doi.org/10.1016/S0140-6736(20)30566-3; Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. PMID: 31986264 https://doi.org/10.1016/S0140-6736(20)30183-5; Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769–777. PMID: 32176772 https://doi.org/10.1093/cid/ciaa272; Interleukin-6 Inhibitors: Selected Clinical Data URL: https://www.covid19treatmentguidelines.nih.gov/tables/table-4b/ [Дата обращения 17 июня 2021 г.]; Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3:CD013881. PMID: 33734435 https://doi.org/10.1002/14651858.CD013881; Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 – Cooling the Inflammatory Soup. N Engl J Med. 2021;384(16):1564–1565. PMID: 33631064 https://doi.org/10.1056/NEJMe2103108; Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181(1):32–40. PMID: 33080017 https://doi.org/10.1001/jamainternmed.2020.6820; CAR-T-клетки: Иммунотерапия опухолей. URL: https://www.mybeckman.ru/resources/research-areas/immunotherapy/about-car-tcells [Дата обращения 17 июня 2021 г.]; Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2):275–281. PMID: 26584195 https://doi.org/10.1097/CCM.0000000000001402; Monteagudo LA, Boothby A, Gertner E. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome. ACR Open Rheumatol. 2020;2(5):276–282. PMID: 32267081 https://doi.org/10.1002/acr2.11135; Barkas F, Ntekouan SF, Kosmidou M, Liberopoulos E, Liontos A, Milionis H. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 May 17:keab447. PMID: 33999135 https://doi.org/10.1093/rheumatology/keab447 Online ahead of print.; Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of antiinflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. PMID: 32222466 https://doi.org/10.1016/j.clim.2020.108393; Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402. PMID: 32113509 https://doi.org/10.1016/S1473-3099(20)30132-8; Fact sheet for healthcare providers emergency use authorization (EUA) of baricitinib. URL: https://www.fda.gov/media/143823/download [Дата обращения 16 июня 2021 г.]; Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al.; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384(9):795–807. PMID: 33306283 https://doi.org/10.1056/NEJMoa2031994; Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallelgroup COV-BARRIER phase 3 trial. medRxiv 2021.04.30.21255934. https://doi.org/10.1101/2021.04.30.21255934 Available at: https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1 [Accessed Jul 07, 2021]; Corticosteroids: Selected Clinical Data. URL: https://www.covid19treatmentguidelines.nih.gov/tables/table-4a/ [Accessed 17 июня 2021 г.]; Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98. PMID: 15634032 https://doi.org/10.2165/00003088-200544010-00003; Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized with Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin Infect Dis. 2021;72(9):e373–e381. PMID: 32785710 https://doi.org/10.1093/cid/ciaa1177; Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(13):1298–1306. PMID: 32876689 https://doi.org/10.1001/jama.2020.16761; Li Q, Li W, Jin Y, Xu W, Huang C, Li L, et al. Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. Infect Dis Ther. 2020;9(4):823–836. PMID: 32880102 https://doi.org/10.1007/s40121-020-00332-3; Angus D C, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324(13):1317–1329. PMID: 32876697 https://doi.org/10.1001/jama.2020.17022; Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772. PMID: 33844996 https://doi.org/10.1016/S2213-2600(21)00160-0; San-Juan R, Fernández-Ruiz M, López-Medrano F, Aguado JM. Inhaled budesonide for early treatment of COVID-19. Lancet Respir Med. 2021;9(7):e58. PMID: 33991508 https://doi.org/10.1016/S2213-2600(21)00211-3; Lachant DJ, Lachant NA, Kouides P, Rappaport S, Prasad P, White RJ. Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection. J Thromb Haemost. 2020;18(10):2640–2645. PMID: 33448631 https://doi.org/10.1111/jth.15032; Rivera-Caravaca JM, Núñez-Gil IJ, Vivas D, Viana-Llamas MC, Uribarri A, Becerra-Muñoz VM, et al. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. Eur J Clin Invest. 2021;51(1):e13436. PMID: 33080051 https://doi.org/10.1111/eci.13436; Llitjos J-F, Leclerc M, Chochois C, Monsallier J-M, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743–1746. PMID: 32320517 https://doi.org/10.1111/jth.14869; Martin TA, Wan DW, Hajifathalian K, Tewani S, Shah SL, Mehta A, et al. Gastrointestinal Bleeding in Patients with Coronavirus Disease 2019: A Matched Case-Control Study. Am J Gastroenterol. 2020;115(10):1609–1616. PMID: 32796176 https://doi.org/10.14309/ajg.0000000000000805; Shah A, Donovan K, McHugh A, Pandey M, Aaron L, Bradbury CA, et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. Crit Care. 2020;24(1):561. PMID: 32948243 https://doi.org/10.1186/s13054-020-03260-3; Horby PW, Pessoa-Amorim G, Staplin N, Emberson JR, Campbell M, Spata E, et al. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv 2021.06.08.21258132 https://doi.org/10.1101/2021.06.08.21258132 URL: https://www.medrxiv.org/content/10.1101/2021.06.08.21258132v1 [Дата обращения 7 июля 2021 г.]; Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524–e533. PMID: 33930350 https://doi.org/10.1016/S2352-3026(21)00105-8; Pereira AA, de Oliveira Andrade A, de Andrade Palis A, Cabral AM, Lima Barreto CG, de Souza DB, et al. Non-pharmacological treatments for COVID-19: current status and consensus. Research on Biomedical Engineering. 2021;1–16. PMCID: PMC7809889 https://doi.org/10.1007/s42600-020-00116-1 [Epub ahead of print]; Журавель С.В., Гаврилов П.В., Кузнецова Н.К., Уткина И.И., Талызин А.М., Александрова В.Э. Клинический случай: термический гелий в лечении пневмонии, вызванной новой коронавирусной инфекцией COVID-19 (SARS-CoV-2). Вестник медицинского института «Реавиз». Реабилитация, Врач и Здоровье. 2021;1(49):5–10. https://doi.org/10.20340/vmi-rvz.2021.1.COVID.1; Левина О.А., Евсеев А.К., Шабанов А.К., Кулабухов В.В., Кутровская Н.Ю., Горончаровская И.В. и др. Безопасность применения гипербарической оксигенации при лечении COVID-19. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2020;9(3):314–320. https://doi.org/10.23934/2223-9022-2020-9-3-314-320; Шогенова Л.В., Варфоломеев С.Д., Быков В.И., Цыбенова С.Б., Рябоконь А.М., Журавель С.В. и др. Влияние термической гелий-кислородной смеси на вирусную нагрузку при COVID-19. Пульмонология. 2020;30(5):533–543. https://doi.org/10.18093/0869-0189-2020-30-5-533-543; https://www.jnmp.ru/jour/article/view/1204

Διαθεσιμότητα: https://www.jnmp.ru/jour/article/view/1204
https://doi.org/10.23934/2223-9022-2021-10-3-438-451

Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines ; Оптимальная стратегия лечения хронического коронарного синдрома – данные новых исследований в сравнении с действующими рекомендациями

Συγγραφείς: L. Bershtein L., E. Zbyshevskaya V., V. Gumerova E., Л. Берштейн Л., Е. Збышевская В., В. Гумерова Е.

Συνεισφορές: Sub-grant under the grant U01HL105907 of the Department of Health and Human Services, Health Service, National Institutes of Health / National Heart, Lung and Blood Institute of the United States of 07/22/2011 to conduct a multicenter, multinational clinical study “International Study of Comparative Health Effectiveness of Drug and Invasive Approaches” ISCHEMIA. PP-XAR-RU-0848-1, Субгрант по гранту U01HL105907 Министерства здравоохранения и социальных служб, службы здравоохранения, национальных институтов здравоохранения/Национального института заболеваний сердца, легких и крови США от 22.07.2011 на проведение многоцентрового, многонационального клинического исследования «Международное исследование сравнительной эффективности для здоровья при медикаментозном и инвазивном подходах» ISCHEMIA

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 5 (2021); 761-770 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 5 (2021); 761-770 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: chronic coronary syndromes, revascularization, antithrombotic therapy, хронический коронарный синдром, реваскуляризация, антитромботическая терапия, рандомизированные исследования, сердечно-сосудистые осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2589/2234; Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541-619. DOI:10.1093/eurheartj/ehu278.; Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI:10.1093/eurheartj/ehy394.; Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.; Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44-e164. DOI:10.1016/j.jacc.2012.07.013.; Берштейн Л.Л., Збышевская Е.В., Катамадзе Н.О., и др. ISCHEMIA - крупнейшее в истории рандомизированное исследование по стабильной ишемической болезни сердца. Исходные характеристики включенных пациентов на примере российского центра. Кардиология. 2017;57(10):12-9. DOI:10.18087/cardio.2017.10.10038.; Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232-40. DOI:10.1001/jamainternmed.2013.12855.; Rajkumar CA, Nijjer SS, Cole GD, et al. 'Faith Healing' and 'Subtraction Anxiety' in Unblinded Trials of Procedures: Lessons from DEFER and FAME-2 for End Points in the ISCHEMIA Trial. Circ Cardiovasc Qual Outcomes. 2018;11:e004665. DOI:10.1161/CIRCOUTCOMES.118.004665.; Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379(3):250-259. DOI:10.1056/NEJMoa1803538.; Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol. 1990 Nov 6;66(16):44G-47G. DOI:10.1016/0002-9149(90)90395-h. PMID: 2239714.; Hochman JS, Reynolds HR, Bangalore S, et al.; ISCHEMIA Research Group. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiol. 2019;4(3):273-86. DOI:10.1001/jamacardio.2019.0014.; Maron DJ, Hochman JS, Reynolds HR, et al.; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-407. DOI:10.1056/NEJMoa1915922.; Spertus JA, Jones PG, Maron DJ, et al.; ISCHEMIA Research Group. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020;382(15):1408-19. DOI:10.1056/NEJMoa1916370.; Chan PS, Jones PG, Arnold SA, Spertus JA. Development and validation of a short version of the Seattle angina questionnaire. Circ Cardiovasc Qual Outcomes. 2014;7(5):640-7. DOI:10.1161/CIRCOUTCOMES.114.000967.; Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664.; Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027-35. DOI:10.1016/j.cjca.2017.06.001.; Cannon CP, Khan I, Klimchak AC, et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017;2(9):959-66. DOI:10.1001/jamacardio.2017.2289.; Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-30. DOI:10.1056/NEJMoa1709118.; Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23): 2736-47. DOI:10.1161/CIRCULATIONAHA.110.009449.; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. DOI:10.1016/s0140-6736(96)09457-3.; Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. DOI:10.1056/NEJMoa1500857.; Steg PG, Bhatt DL, Simon T, et al.; THEMIS Steering Committee and Investigators. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-20. DOI:10.1056/NEJMoa1908077.; Steg PG, Bhatt DL. Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics? Circulation. 2018;137(14):1429-31. DOI:10.1161/CIRCULATIONAHA.117.033442.; Leiter LA, Bhatt DL, McGuire DK, et al.; THEMIS Steering Committee and Investigators. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. J Am Coll Cardiol. 2021;77(19):2366-77. DOI:10.1016/j.jacc.2021.03.298.; Bainey KR, Welsh RC, Connolly SJ, et al.; COMPASS Investigators. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020;141(14):1141-1151. DOI:10.1161/CIRCULATIONAHA.119.044598.; Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol. 2019;73(2):121-30. DOI:10.1016/j.jacc.2018.10.048.; Boden WE, O'Rourke RA, Teo KK, et al.; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-16. DOI:10.1056/NEJMoa070829.; Chatterjee S. Comparison of the ISCHEMIA Trial Population to Patients Undergoing Percutaneous Coronary Intervention in US Practice: A Cathpci National Cardiovascular Data Registry (NCDR) Research to Practice (R2P) Initiative [cited by Jun 15, 2021]. Available from: https://scai.confex.com/scai/2021/meetingapp.cgi/Paper/14413.; Stone G. Impact of Completeness of Revascularization on Clinical Outcomes in Patients With Stable Ischemic Heart Disease Treated With an Invasive Versus Conservative Strategy: The ISCHEMIA Trial [cited by Jun 15, 2021]. Available from: https://www.acc.org/-/media/Clinical/PDF-Files/Approved-PDFs/2021/05/11/ACC21/17May-Mon/1230pmET-ISCHEMIA-SIHD-acc-2021.pdf.; Weintraub WS, Hartigan PM, Mancini GBJ, et al. Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019;12(2):e005079. DOI:10.1161/CIRCOUTCOMES.118.005079.; Bangalore S, Maron DJ, Stone GW, Hochman JS. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2020;142(9):841-57. DOI:10.1161/CIRCULATIONAHA.120.048194.; Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2020;25(11):4076. DOI:10.15829/1560-4071-2020-4076.; Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease [cited by Jun 15, 2021]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heartattack-or-stroke-in-high-risk-patients-with-coronary-artery-disease.html.; Darmon A, Bhatt DL, Elbez Y, et al. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018;39(9):750-757a. DOI:10.1093/eurheartj/ehx658.; Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL. Atherosclerosis. 2018;275:262-4. DOI:10.1016/j.atherosclerosis.2018.06.821.; Liu H, Yu J, Chen F, Li J, Hu D. Inpatients with coronary heart disease have a high prevalence of chronic kidney disease based on estimated glomerular filtration rate (eGFR) in China. Heart Vessels. 2007;22(4):223-8. DOI:10.1007/s00380-006-0964-7.; Kownator S, Cambou JP, Cacoub P, et al. Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study. Arch Cardiovasc Dis. 2009;102(8-9):625-31. DOI:10.1016/j.acvd.2009.05.004.; Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: Insights from the COMPASS Trial. Circulation. 2020;141(23):1841-54. DOI:10.1161/CIRCULATIONAHA.120.046448.; https://www.rpcardio.com/jour/article/view/2589

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2589
https://doi.org/10.20996/1819-6446-2021-10-02

Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention ; Антитромботическая терапия у пациентов с фибрилляцией предсердий при чрескожных коронарных вмешательствах

Συγγραφείς: A. Panov V., А. Панов В.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 4 (2021); 628-637 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 4 (2021); 628-637 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: чрескожное коронарное вмешательство, фибрилляция предсердий, варфарин, прямые пероральные антикоагулянты, двойная и тройная антитромботическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2546/2215; Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-34. DOI:10.1093/europace/eun369.; Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128(7):721-8. DOI:10.1161/CIRCULATIONAHA.113.002927.; Fox KAA, Velentgas P, Camm AJ, et al. Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open. 2020;3(2):e200107. DOI:10.1001/jamanetworkopen.2020.0107.; Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422-34. DOI:10.1093/eurheartj/ehi505; Steffel1 Y, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Apr 25;euab065. DOI:10.1093/europace/euab065.; Depta JP, Cannon CP, Fonarow GC, et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009;104(9):1171-8. DOI:10.1016/j.amjcard.2009.06.027.; Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17. DOI:10.1056/NEJMoa1107039.; Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12. DOI:10.1016/S01406736(06)68845-4.; Leon MB, Baim DS, Popma JJ, et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998; 339(23):1665-71. DOI:10.1056/NEJM199812033392303.; Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 2007;167(2):117-24. DOI:10.1001/archinte.167.2.117.; Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-41. DOI:10.1001/archinternmed.2010.271.; Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-24. DOI:10.1056/NEJMoa1817083.; Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. DOI:10.1016/S01406736(12)62177-1.; Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169(4):472-8.e5. DOI:10.1016/j.ahj.2014.12.006.; Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-24. DOI:10.1056/NEJMoa1708454.; Vranckx P, Valgimigli M, Eckardt L, et al. Edoxabanbased versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients withatrial fibrillation (ENTRUSTAF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-43. DOI:10.1056/NEJMoa1708454.; Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634-40. DOI:10.1161/CIRCULATIONAHA.112.115386.; Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summa-ry. Circ Cardiovasc Interv. 2011;4(5):522-34. DOI:10.1161/CIRCINTERVENTIONS.111.965186.; Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121(18):2067-70. DOI:10.1161/CIRCULATIONAHA.109.924944.; Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854-64. DOI:10.1093/eurheartj/ehr204.; Fiedler K.A., Maeng M., Mehilli J., et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65(16):1619-29. DOI:10.1016/j.jacc.2015.02.050.; Фибрилляция и трепетание предсердий. Рекомендации Российского Кардиологического Общества (2020) [цитировано 30.06.2021. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf.; Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российское кардиологическое общество, Ассоциация сердечно-сосудистых хирургов России. Российский Кардиологический Журнал. 2020;25(11):4103. DOI:10.15829/1560-4071-2020-4103.; Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Рекомендации Российского Кардиологического Общества (2020). Российский Кардиологический Журнал. 2020;26(4):4449. DOI:10.15829/1560-4071-2021-4449.; Стабильная ишемическая болезнь сердца. Рекомендации Российского Кардиологического Общества (2020). Российский Кардиологический Журнал. 2020;25(11):201-51. DOI:10.15829/1560-4071-2020-4076.; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;77(5):629-58. DOI:10.1016/j.jacc.2020.09.011.; Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2019;141(9):781-3. DOI:10.1161/CIRCULATIONAHA.119.044584.; Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018;138(5):527-36. DOI:10.1161/CIRCULATIONAHA.120.050438.; Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the EHRA, EAPCI, ACCA endorsed by the HRS, APHRS, LAHRS, CASSA. Europace. 2019;21(2):192-3. DOI:10.1093/europace/euy174.; Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-9. DOI:10.1056/NEJMoa1209979.; Price MJ, Berger PB, Teirstein PS, et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105. DOI:10.1001/jama.2011.290.; Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159-64. DOI:10.1016/j.jacc.2012.02.026.; Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621-31. DOI:10.1056/NEJMoa1907096.; Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381():1103-13. DOI:10.1056/NEJMoa1904143.; Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139(5):604-16. DOI:10.1161/CIRCULATIONAHA.118.036768.; Berry NC, Mauri L, Steg PG, et al. Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial. Circ Cardiovasc Interv. 2020;13(4):e008349. DOI:10.1161/CIRCINTERVENTIONS.119.008349.; Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618-23. DOI:10.1016/j.amjcard.2008.08.021.; Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebocontrolled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. DOI:10.1038/clpt.2010.219.; Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44. DOI:10.1001/jama.2009.261.; Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. DOI:10.1056/NEJMoa1007964.; Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents,and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267-74. DOI:10.1016/j.jcin.2013.06.015.; Rubboli A, Lip GYH. Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):197-8. DOI:10.1093/ehjcvp/pvaa003.; Baker NC, O’Connell EW, Htun WW, et al. Safety of coronary angiography andpercutaneous coronary intervention via the radial versus femoral route inpatients on uninterrupted oral anticoagulation with warfarin. Am Heart J. 2014;168(4):537-44. DOI:10.1016/j.ahj.2014.06.016.; Chongprasertpon N, Zebrauskaite A, Coughlan JJ, et al. Performing diagnostic radial access coronary angiog-raphy on uninterrupted direct oral anticoagulant therapy: a prospective analysis. Open Heart. 2019;6(1):e0010. DOI:10.1136/openhrt-2019-001079.; Giustino G, Chieffo A, Palmerini T et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851-64. DOI:10.1016/j.jacc.2016.07.760.; Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI:10.1093/eurheartj/ehy394.; Knuuti J, Wijns W, Saraste A, Capodanno D, et al. ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis a management of chronic coronary syndromes. Eur Heart J. 2020;41(3):40777. DOI:10.1093/eurheartj/ehz425; Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. DOI:10.1056/NEJMoa0904327.; Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. DOI:10.1056/NEJMoa0706482.; Jackson LR, Ju C, Zettler M, Messenger JC, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. ACC Cardiovasc Interv. 2015;8(14):1880-9. DOI:10.1016/j.jcin.2015.08.018.; Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the ESC and of the EACTS. Eur Heart J. 2018;39(3):213-60. DOI:10.1093/eurheartj/ehx419.; Lau WCY, Douglas IJ, Wong ICK, et al. Thromboembolic, bleeding, and mortalityrisks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: a population-based study. Heart Rhythm. 2020;17(1):33-40. DOI:10.1016/j.hrthm.2019.07.034.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin inpatients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. DOI:10.1016/S0140-6736(13)62343-0.; Genereux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036-45. DOI:10.1016/j.jacc.2015.06.1323.; ten Berg JM, de Veer A, Oldgren J, Steg PG, et al. RE-DUAL PCI Steering Committee and Investigators. Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: the RE-DUAL PCI trial subanalysis. JACC Cardiovasc Interv. 2019;12(23):2331-41. DOI:10.1016/j.jcin.2019.08.039.; Rubboli A, Valgimigli M, Capodanno D, et al. Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. Eur Heart J – Cardiovascular Pharmacotherapy. 2021;7(1):68-73. DOI:10.1093/ehjcvp/pvaa047.; Rubboli A, Lisi M. After the AUGUSTUS trial, should apixaban be the only directoral anticoagulant to be used in triple therapy in atrial fibrillation patients under-going percutaneous coronary intervention? Cardiovasc Drugs Ther. 2019;33(4):499-500. DOI:10.1007/s10557-019-06886-w.; Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e326S-e350S. DOI:10.1378/chest.11-2298.; Eikelboom JW, Connolly S J, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14):1319-1330. DOI:10.1056/NEJMoa1709118.; Mega J, Braunwald E, Wiviott S, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9-19. DOI:10.1056/NEJMoa1112277.; Pradaxa. Summary of product characteristics. European Medicines Agency DSoPC [cited by Jun 30, 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.; van Es RF, Jonker JJ, Verheugt FW, et al. Antithrombotics in the Secondary Prevention of Events in CoronaryThrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109-13. DOI:10.1016/S0140-6736(02)09409-6.; Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-74. DOI:10.1056/NEJMoa020496.; Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic im-pact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64(14):1430-6. DOI:10.1016/j.jacc.2014.07.957.; Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13. DOI:10.1056/NEJMoa1904143.; https://www.rpcardio.com/jour/article/view/2546

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2546
https://doi.org/10.20996/1819-6446-2021-07-02

Features of Risk Stratification, Diagnosis and Secondary Prevention in Patients with Multifocal Arterial Disease. Part 2: Treatment Options ; Особенности вторичной профилактики у пациентов с мультифокальным артериальным поражением. Часть 2: возможности лечения

Συγγραφείς: V. Grachev G., S. Vedenskaya S., O. Smolenskaya G., В. Грачев Г., С. Веденская С., О. Смоленская Г.

Συνεισφορές: The publication of the article is supported by Bayer, but it did not affect his own opinion of the authors, Публикация статьи поддержана компанией Байер, что никоим образом не повлияло на собственное мнение авторов

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 239-248 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 239-248 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: cardiovascular disease, polyvascular disease, screening, risk assessment, secondary prevention, antithrombotic therapy, сердечно-сосудистые заболевания, мультифокальное артериальное поражение, скрининг, стратификация риска, вторичная профилактика, антитромботическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2376/2145; Aboyans V, Ricco JB, Bartelink MEL, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. DOI:10.1093/eurheartj/ehx095.; Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.; Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eu-rheartj/ehy339.; Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (In Russ.) [Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2020;25(3):3786]. DOI:10.15829/1560-4071-2020-3-3786.; SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. DOI:10.1056/NEJMoa1511939.; Fudim M, Jones WS. New Curveball for Hypertension Guidelines? Circulation. 2018;138(17):1815- 8. DOI:10.1161/CIRCULATIONAHA.118.036409.; Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55(1):48-53. DOI:10.1161/HYPERTENSIONAHA.109.142240.; Itoga NK, Tawfik DS, Lee CK, et al. Association of Blood Pressure Measurements With Peripheral Artery Disease Events. Circulation. 2018;138(17):1805-14. DOI:10.1161/CIRCULATIONAHA.118.033348.; Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107(5):753- 6. DOI:10.1161/01.cir.0000049640.46039.52.; Ostergren J, Sleight P, Dagenais G, et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17-24. DOI:10.1016/j.ehj.2003.10.033.; ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. DOI:10.1056/NEJMoa0801317.; Armstrong EJ, Chen DC, Singh GD, et al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med. 2015;20(3):237-44. DOI:10.1177/1358863X15574321.; Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013(9):CD005508. DOI:10.1002/14651858.CD005508.pub3.; Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87(11):1284-6. DOI:10.1016/s0002-9149(01)01521-1.; Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934- 43. DOI:10.1016/S2213-8587(18)30290-0.; Jukema JW, Szarek M, Zijlstra LE, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;74(9):1167-76. DOI:10.1016/j.jacc.2019.03.013.; Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-50. DOI:10.1161/CIRCULATIONAHA.117.032235.; Verma S, Bhatt DL, Bain SC, et al. LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018;137(20):2179-83. DOI:10.1161/CIRCULATIONAHA.118.033898.; Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. DOI:10.1056/NEJMoa1611925.; Verma S, Mazer CD, Al-Omran M, et al. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137(4):405-7. DOI:10.1161/CIRCULATIONAHA.117.032031.; Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020;142(8):734- 47. DOI:10.1161/CIRCULATIONAHA.119.044775.; McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303.; Li D, Yang JY, Wang T, et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials. Diabetes Metab. 2018 Nov;44(5):410-4. DOI:10.1016/j.diabet.2018.02.001.; Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab. 2018;20(6):1531-4. DOI:10.1111/dom.13255.; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329- 39. DOI:10.1016/s0140-6736(96)09457-3.; Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. DOI:10.1093/eurheartj/ehx419.; Hiatt WR, Fowkes FG, Heizer G, Berger JS, et al. EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017;376(1):32- 40. DOI:10.1056/NEJMoa1611688.; Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17. DOI:10.1056/NEJMoa060989.; Bhatt DL, Flather MD, Hacke W, et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982-8. DOI:10.1016/j.jacc.2007.03.025.; Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-66. DOI:10.1056/NEJMoa1409312.; Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. DOI:10.1056/NEJMoa1500857.; Secemsky EA, Yeh RW, Kereiakes DJ, et al. Dual Antiplatelet Therapy Study Investigators. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017;10(9):942- 954. DOI:10.1016/j.jcin.2017.02.013.; Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719-28. DOI:10.1016/j.jacc.2016.03.524.; Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS- TIMI 54. Eur Heart J. 2016;37(14):1133-42. DOI:10.1093/eurheartj/ehv531.; Fender AC, Rauch BH, Geisler T, Schror K. Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation? Thromb Haemost. 2017;117(11):2013-25. DOI:10.1160/TH17-03-0219.; Borissoff JI, Joosen IA, Versteylen MO, et al. Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. JACC Cardiovasc Imaging. 2012;5(12):1201-10. DOI:10.1016/j.jcmg.2012.01.023.; Gurbel PA, Bliden KP, Navickas I, et al. Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: what are we overlooking? J Thromb Haemost. 2007;5(11):2300-1. DOI:10.1111/j.1538-7836.2007.02749.x.; Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282(21):2058-67. DOI:10.1001/jama.282.21.2058.; Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S-69S. DOI:10.1016/s0735-1097(02)02776-6.; Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519-26. DOI:10.1093/eurheartj/ehi485.; Alexander JH, Lopes RD, James S, et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708. DOI:10.1056/NE-JMoa1105819.; Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. DOI:10.1056/NEJMoa1112277.; Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. DOI:10.1056/NE-JMoa1709118.; Connolly SJ, Eikelboom JW, Bosch J, et al. COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-18. DOI:10.1016/S0140-6736(17)32458-3.; Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-29. DOI:10.1016/S0140-6736(17)32409-1.; Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139(9):1134-1145. DOI:10.1161/CIRCULATIONAHA.118.035864.; Российское кардиологическое общество (Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. DOI:10.15829/1560-4071-2020-4076.; Maron DJ, Hochman JS, Reynolds HR, et al. ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-407. DOI:10.1056/NE-JMoa1915922.; https://www.rpcardio.com/jour/article/view/2376

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2376
https://doi.org/10.20996/1819-6446-2021-03-02

Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries

Συγγραφείς: O. V. Reshetko, A. V. Sokolov, N. V. Furman

Πηγή: Качественная клиническая практика, Vol 0, Iss 1, Pp 83-96 (2019)

Θεματικοί όροι: регистры, фибрилляция предсердий, антитромботическая терапия, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Περιγραφή αρχείου: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/440; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Σύνδεσμος πρόσβασης: https://doaj.org/article/e8de1f751f9242e6a8b7874ad9f49a87

CARDIAC INSUFFICIENCY FREQUENCY AND ANTI-THROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE INFORMATION PROVIDED BY THE HOSPITAL REGISTR KRAF

Συγγραφείς: Nikolai Gamletovich Gogolashvili, Alexander Aleksandrovich Tuchkov, Roman Anatolyevich Yaskevich

Πηγή: Siberian Journal of Life Sciences and Agriculture, Vol 11, Iss 5-2, Pp 28-33 (2019)

Θεματικοί όροι: фибрилляция предсердий, сердечная недостаточность, антитромботическая терапия, Agriculture, Science

Περιγραφή αρχείου: electronic resource

Relation: http://journal-s.org/index.php/vmno/article/view/12184; https://doaj.org/toc/2658-6649; https://doaj.org/toc/2658-6657

Σύνδεσμος πρόσβασης: https://doaj.org/article/097992e321e14f008be5e8c6101adac3